

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2013/121387 A1

(43) International Publication Date

22 August 2013 (22.08.2013)

(51) International Patent Classification:

C07D 401/04 (2006.01) *C07D 241/26* (2006.01)
C07D 401/10 (2006.01) *A61K 31/444* (2006.01)
C07D 401/14 (2006.01) *A61K 31/497* (2006.01)
C07D 413/10 (2006.01) *A61P 33/06* (2006.01)

(21) International Application Number:

PCT/IB2013/051235

(22) International Filing Date:

15 February 2013 (15.02.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/600,324 17 February 2012 (17.02.2012) US

(71) Applicants: UNIVERSITY OF CAPE TOWN [ZA/ZA]; Bremner Building Lovers', Walk Private Bag X3, 7701 Rondebosch (ZA). MMV MEDICINES FOR MALARIA VENTURE [CH/CH]; 20 route de Pré-Bois, ICC, CH-1215 Geneva (CH).

(72) Inventors: YOUNIS, Yassir; 6 Rhodesview, CNR Sawkins & Park RD, Rosebank, 7700 CapeTown (ZA). CHIBALE, Kelly; 32 Franklin Road, 7708 Claremont (ZA). WITTY, Michael, John; 2 Bridleway, Whitfield, Dover Kent CT16 3NH (GB). WATERSON, David; Rue de la Colombière 12, CH-1260 Nyon (CH).

(74) Agent: REUTELER & CIE SA; Chemin de la Vuarpillière 29, CH-1260 Nyon (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

WO 2013/121387 A1

(54) Title: ANTI -MALARIAL AGENTS

(57) Abstract: The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

ANTI-MALARIAL AGENTS

Field of the Invention

The present invention relates to novel anti-malarial agents. Specifically, the present invention is related to agents useful for the preparation of a pharmaceutical formulation 5 for preventing or treating malaria and methods of their use and manufacture.

Background of the Invention

Malaria is caused by protozoan parasites of the genus *Plasmodium* that infect and destroy red blood cells, leading to fever, severe anemia, cerebral malaria and, if untreated, death. *Plasmodium falciparum* is the dominant species in sub-Saharan Africa, 10 and is responsible for the almost 1 million deaths each year. The disease burden is heaviest in African children under 5 years of age and in pregnant women. *Plasmodium vivax* causes 25-40% of the global malaria burden, particularly in South and Southeast Asia, and Central and South America. The other two main species that are known to infect humans are *Plasmodium ovale* and *Plasmodium malariae*.
15 Malaria is a disease that is prevalent in many developing countries. Approximately 40% of the world's population lives in countries where the disease is endemic; approximately 247 million people suffer from the disease every year.

Various medications are presently used for the treatment of malaria. However, many of these medications are costly and some exhibit significant toxicity and undesirable side 20 effects in humans. Drugs used for treating malaria include artemisinin and its derivatives, chloroquine, quinine, mefloquine, amodiaquine, atovaquone/proguanil, doxycycline, hydroxychloroquine, halofantrine, pyrimethamine-sulfadoxine, and primaquine.

However, the widespread emergence of drug resistance of malaria parasites in many 25 tropical countries has compromised many of the current chemotherapies and there is a continued need for new chemotherapeutic approaches. Accordingly, this invention provides novel potent anti-malarial agents and methodology of treating malaria using novel potent anti-malarial agents.

Summary of the Invention

The present invention is directed towards novel aminopyrazine derivatives which are useful in the treatment and/or prophylaxis of malaria, pharmaceutical formulation, use and manufacture thereof.

5 A first aspect of the invention provides an aminopyrazine derivative according to the invention or a pharmaceutically acceptable salt thereof or a pharmaceutically active derivative thereof.

A second aspect of the invention relates to an aminopyrazine derivative or a pharmaceutically acceptable salt thereof or a pharmaceutically active derivative thereof
10 according to the invention for use as a medicament.

A third aspect of the invention relates to the use of an aminopyrazine derivative according to the invention or a pharmaceutically acceptable salt thereof or a pharmaceutically active derivative thereof, for the preparation of a pharmaceutical composition for the prevention and/or treatment of malaria.

15 A fourth aspect of the invention resides in a pharmaceutical formulation comprising at least one aminopyrazine derivative according to the invention or a pharmaceutically acceptable salt thereof or a pharmaceutically active derivative thereof, and a pharmaceutically acceptable carrier, diluent or excipient thereof.

A fifth aspect of the invention relates to an aminopyrazine derivative according to the
20 invention or a pharmaceutically acceptable salt thereof or a pharmaceutically active derivative thereof, for use in the prevention and/or treatment of malaria.

A sixth aspect of the invention resides in a method for preventing and/or treating malaria in a patient. The method comprises administering an aminopyrazine derivative according to the invention or a pharmaceutically acceptable salt thereof or a
25 pharmaceutically active derivative thereof in a patient in need thereof.

A seventh aspect of the invention provides a process for the preparation of an aminopyrazine derivative according to the invention or a pharmaceutically acceptable salt thereof or a pharmaceutically active derivative thereof according to the invention and intermediates thereof.

30 An eighth aspect of the invention provides an intermediate of formula (v) according to the invention.

A ninth provides an intermediate of formula (viii) according to the invention.

A tenth aspect provides an intermediate of formula (ix) according to the invention.

An eleventh aspect provides a process for the preparation of a compound of Formula (I) comprising a step of reacting an intermediate of formula (v).

A twelfth aspect provides a process for the preparation of a compound of Formula (I) comprising a step of reacting an intermediate of formula (viii).

A thirteenth aspect provides a process for the preparation of a compound of Formula (I) comprising a step of reacting an intermediate of formula (xix).

A fourteenth aspect provides intermediates useful in the preparation of a compound of Formula (I) and processes for the preparation thereof.

10 Other features and advantages of the invention will be apparent from the following detailed description.

Detailed Description of the invention

The following paragraphs provide definitions of the various chemical moieties that make up the compounds according to the invention and are intended to apply uniformly through-out the specification and claims, unless an otherwise expressly set out definition provides a broader definition.

The term "C₁-C₆ alkyl" when used alone or in combination with other terms, comprises a straight chain or branched C₁-C₆ alkyl which refers to monovalent alkyl groups having 1 to 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl, n-pentyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, and the like.

The term "C₂-C₆ alkenyl" when used alone or in combination with other terms, comprises a straight chain or branched C₂-C₆ alkenyl. Particularly, it refers to groups having 2 to 6 carbon atoms and having at least 1 or 2 sites of alkenyl unsaturation. It may have any available number of double bonds in any available positions, and the configuration of the double bond may be the (E) or (Z) configuration. This term is exemplified by groups such as vinyl, allyl, isopropenyl, 1-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-ethyl-1-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, and the like. Among others, are vinyl or

ethenyl (-CH=CH₂), n-2-propenyl (allyl, -CH₂CH=CH₂), isopropenyl, 1-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, and 3-methyl-2-butenyl and the like.

The term "C₂-C₆ alkynyl" when used alone or in combination with other terms, comprises a straight chain or branched C₂-C₆ alkynyl. It may have any available number of triple bonds in any available positions. This term is exemplified by groups such as alkynyl groups that may have a carbon number of 2-6, and optionally a double bond, such as ethynyl (-C≡CH), 1-propynyl, 2-propynyl (propargyl: -CH₂C≡CH), 2-butyynyl, 2-pentene-4-ynyl, and the like.

The term "heteroalkyl" refers to C₁-C₁₂-alkyl, preferably C₁-C₆-alkyl, wherein at least one carbon has been replaced by a heteroatom selected from O, N or S, including 2-methoxy ethyl and the like.

The term "aryl" refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g. phenyl) or multiple condensed rings (e.g., indenyl, naphthyl). Aryl include phenyl, naphthyl, anthryl, phenanthrenyl and the like.

The term "C₁-C₆ alkyl aryl" refers to aryl groups having a C₁-C₆ alkyl substituent, including methyl phenyl, ethyl phenyl and the like.

The term "aryl C₁-C₆ alkyl" refers to C₁-C₆ alkyl groups having an aryl substituent, including 3-phenylpropanyl, benzyl and the like.

The term "heteroaryl" refers to a monocyclic heteroaromatic, or a bicyclic or a tricyclic fused-ring heteroaromatic group. Particular examples of heteroaromatic groups include optionally substituted pyridyl, pyrrolyl, pyrimidinyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, isoquinolinyl, 3H-indolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoazolyl, quinolizinyl, quinazolinyl, phthalazinyl, quinoxalinyl, cinnolinyl, napthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, carbazolyl, xanthenyl or benzoquinolyl.

The term "C₁-C₆ alkyl heteroaryl" refers to heteroaryl groups having a C₁-C₆ alkyl substituent, including methyl furyl and the like.

The term “heteroaryl C₁-C₆ alkyl” refers to C₁-C₆ alkyl groups having a heteroaryl substituent, including furyl methyl and the like.

The term “C₂-C₆ alkenyl aryl” refers to an aryl groups having a C₂-C₆ alkenyl substituent, including vinyl phenyl and the like.

5 The term “aryl C₂-C₆ alkenyl” refers to a C₂-C₆ alkenyl groups having an aryl substituent, including phenyl vinyl and the like.

The term “C₂-C₆ alkenyl heteroaryl” refers to heteroaryl groups having a C₂-C₆ alkenyl substituent, including vinyl pyridinyl and the like.

10 The term “heteroaryl C₂-C₆ alkenyl” refers to C₂-C₆ alkenyl groups having a heteroaryl substituent, including pyridinyl vinyl and the like.

The term “C₃-C₈-cycloalkyl” refers to a saturated carbocyclic group of from 3 to 8 carbon atoms having a single ring (e.g. cyclohexyl) or multiple condensed rings (e.g. norbornyl). C₃-C₈-cycloalkyl includes cyclopentyl, cyclohexyl, norbornyl and the like.

15 The term “heterocycloalkyl” refers to a C₃-C₈-cycloalkyl group according to the definition above, in which up to 3 carbon atoms are replaced by heteroatoms chosen from the group consisting of O, S, NR, R being defined as hydrogen or methyl. Heterocycloalkyl include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and the like.

20 The term “C₁-C₆ alkyl C₃-C₈-cycloalkyl” refers to C₃-C₈-cycloalkyl groups having a C₁-C₆ alkyl substituent, including methyl cyclopentyl and the like.

The term “C₃-C₈-cycloalkyl C₁-C₆ alkyl” refers to C₁-C₆ alkyl groups having a C₃-C₈-cycloalkyl substituent, including 3-cyclopentyl propyl and the like.

The term “C₁-C₆ alkyl heterocycloalkyl” refers to heterocycloalkyl groups having a C₁-C₆ alkyl substituent, including 4-methylpiperidinyl and the like.

25 The term “heterocycloalkyl C₁-C₆ alkyl” refers to C₁-C₆ alkyl groups having a heterocycloalkyl substituent, including (1-methylpiperidin-4-yl) methyl and the like.

The term “carboxy” refers to the group –C(O)OH.

The term “carboxy C₁-C₆ alkyl” refers to C₁-C₆ alkyl groups having a carboxy substituent, including 2-carboxyethyl and the like.

30 The term “acyl” refers to the group –C(O)R where R includes H, “C₁-C₆ alkyl,” “aryl,” “heteroaryl,” “C₃-C₈-cycloalkyl,” “heterocycloalkyl,” “aryl C₁-C₆ alkyl,” “heteroaryl

C_1 - C_6 alkyl," " C_3 - C_8 -cycloalkyl C_1 - C_6 alkyl" or "heterocycloalkyl C_1 - C_6 alkyl", including acetyl and the like.

The term "acyl C_1 - C_6 alkyl" refers to C_1 - C_6 alkyl groups having an acyl substituent, including 2-acetylethyl and the like.

5 The term "acyl aryl" refers to aryl groups having an acyl substituent, including 2-acetylphenyl and the like.

The term "acyloxy" refers to the group $-OC(O)R$ where R includes H, " C_1 - C_6 alkyl", " C_2 - C_6 alkenyl," " C_2 - C_6 alkynyl," " C_3 - C_8 -cycloalkyl," "heterocycloalkyl," "aryl," "heteroaryl," "aryl C_1 - C_6 alkyl", "heteroaryl C_1 - C_6 alkyl," "aryl C_2 - C_6 alkenyl,"

10 "heteroaryl C_2 - C_6 alkynyl," "aryl C_2 - C_6 alkynyl," "heteroaryl C_2 - C_6 alkynyl," " C_3 - C_8 -cycloalkyl C_1 - C_6 alkyl," or "heterocycloalkyl C_1 - C_6 alkyl", including acyloxy and the like.

The term "acyloxy C_1 - C_6 alkyl" refers to alkyl groups having an acyloxy substituent, including 2-(ethylcarbonyloxy)ethyl and the like.

15 The term "alkoxy" refers to the group $-O-R$ where R includes optionally substituted " C_1 - C_6 alkyl", optionally substituted "aryl", optionally substituted "heteroaryl", optionally substituted "aryl C_1 - C_6 alkyl" or optionally substituted "heteroaryl C_1 - C_6 alkyl".

The term "alkoxy C_1 - C_6 alkyl" refers to C_1 - C_6 alkyl groups having an alkoxy substituent, including methoxyethyl and the like.

The term "alkoxycarbonyl" refers to the group $-C(O)OR$ where R includes " C_1 - C_6 alkyl", "aryl", "heteroaryl", "aryl C_1 - C_6 alkyl", "heteroaryl C_1 - C_6 alkyl" or "heteroalkyl".

25 The term "alkoxycarbonyl C_1 - C_6 alkyl" refers to C_1 - C_6 alkyl groups having an alkoxy carbonyl substituent, including 2-(benzyloxycarbonyl)ethyl and the like.

The term "aminocarbonyl" refers to the group $-C(O)NRR'$ where R and R' are independently H, C_1 - C_6 alkyl, aryl, heteroaryl, "aryl C_1 - C_6 alkyl" or "heteroaryl C_1 - C_6 alkyl," including N-phenyl carbonyl and the like.

30 The term "aminocarbonyl C_1 - C_6 alkyl" refers to C_1 - C_6 alkyl groups having an aminocarbonyl substituent, including 2-(dimethylaminocarbonyl)ethyl, N-ethyl acetamidyl, N,N-Diethyl-acetamidyl and the like.

The term “acylamino” refers to the group $-\text{NRC(O)R}'$ where R and R' are independently H, “C₁-C₆ alkyl,” “C₂-C₆ alkenyl,” “C₂-C₆ alkynyl,” “C₃-C₈-cycloalkyl,” “heterocycloalkyl,” “aryl,” “heteroaryl,” “aryl C₁-C₆ alkyl”, “heteroaryl C₁-C₆ alkyl,” “aryl C₂-C₆ alkenyl,” “heteroaryl C₂-C₆ alkenyl,” “aryl C₂-C₆ alkynyl,” “heteroaryl C₂-C₆ alkynyl,” “C₃-C₈-cycloalkyl C₁-C₆ alkyl,” or “heterocycloalkyl C₁-C₆ alkyl”, including acetylamino and the like.

The term “acylamino C₁-C₆ alkyl” refers to C₁-C₆ alkyl groups having an acylamino substituent, including 2-(propionylamino)ethyl and the like.

The term “ureido” refers to the group $-\text{NRC(O)NR}'\text{R}''$ where R, R' and R'' are independently H, “C₁-C₆ alkyl,” “C₂-C₆ alkenyl,” “C₂-C₆ alkynyl,” “C₃-C₈-cycloalkyl,” “heterocycloalkyl,” “aryl,” “heteroaryl,” “aryl C₁-C₆ alkyl”, “heteroaryl C₁-C₆ alkyl,” “aryl C₂-C₆ alkenyl,” “heteroaryl C₂-C₆ alkenyl,” “aryl C₂-C₆ alkynyl,” “heteroaryl C₂-C₆ alkynyl,” “C₃-C₈-cycloalkyl C₂-C₆ alkyl,” or “heterocycloalkyl C₁-C₆ alkyl,” and where R' and R'' together with the nitrogen atom to which they are attached, can optionally form a 3-8-membered heterocycloalkyl ring.

The term “ureido C₁-C₆ alkyl” refers to C₁-C₆ -alkyl groups having an ureido substituent, including 2-(*N*¹-methylureido)ethyl and the like.

The term “carbamate” refers to the group $-\text{NRC(O)OR}'$ where R and R' are independently “C₁-C₆ alkyl,” “C₂-C₆ alkenyl,” “C₂-C₆ alkynyl,” “C₃-C₈-cycloalkyl,” “heterocycloalkyl,” “aryl,” “heteroaryl,” “C₁-C₆ alkyl aryl”, “heteroaryl C₁-C₆ alkyl,” “aryl C₂-C₆ alkenyl,” “heteroaryl C₂-C₆ alkenyl,” “aryl C₂-C₆ alkynyl,” “heteroaryl C₂-C₆ alkynyl,” “C₃-C₈-cycloalkyl C₁-C₆ alkyl,” or “heterocycloalkyl C₁-C₆ alkyl” and optionally R can also be hydrogen.

The term “amino” refers to the group $-\text{NRR}'$ where R and R' are independently H, “C₁-C₆ alkyl”, “aryl”, “heteroaryl”, “C₁-C₆ alkyl aryl”, “C₁-C₆ alkyl heteroaryl,” “C₃-C₈-cycloalkyl,” or “heterocycloalkyl,” and where R and R', together with the nitrogen atom to which they are attached, can optionally form a 3-8-membered heterocycloalkyl ring.

The term “amino C₁-C₆ alkyl” refers to alkyl groups having an amino substituent, including 2-(1-pyrrolidinyl)ethyl and the like.

The term “ammonium” refers to a positively charged group $-\text{N}^+\text{RR}'\text{R}''$ where R, R' and R'' are independently “C₁-C₆ alkyl”, “C₁-C₆ alkyl aryl”, “C₁-C₆ alkyl heteroaryl,” “C₃-

C₈-cycloalkyl," or "heterocycloalkyl," and where R and R', together with the nitrogen atom to which they are attached, can optionally form a 3-8-membered heterocycloalkyl ring.

5 The term "ammonium C₁-C₆ alkyl" refers to alkyl groups having an ammonium substituent, including 1-ethylpyrrolidinium and the like.

The term "halogen" refers to fluoro, chloro, bromo and iodo atoms.

10 The term "sulfonyloxy" refers to a group -OSO₂-R wherein R is selected from "C₁-C₆ alkyl," "C₁-C₆ alkyl" substituted with halogens, e.g., an -OSO₂-CF₃ group, "C₂-C₆ alkenyl," "C₂-C₆ C₂-C₆ alkynyl," "C₃-C₈-cycloalkyl," "heterocycloalkyl," "aryl," "heteroaryl," "aryl C₁-C₆ alkyl", "heteroaryl C₁-C₆ alkyl," "aryl C₂-C₆ alkenyl," "heteroaryl C₂-C₆ alkenyl," "aryl C₂-C₆ alkynyl," "heteroaryl C₂-C₆ alkynyl," "C₃-C₈-cycloalkyl C₁-C₆ alkyl," or "heterocycloalkyl C₁-C₆ alkyl".

15 The term "sulfamate" refers to a group -OSO₂-NRR' wherein R and R' are independently selected from H, "C₁-C₆ alkyl," "C₂-C₆ alkenyl," "C₂-C₆ alkynyl," "C₃-C₈-cycloalkyl," "heterocycloalkyl," "aryl," "heteroaryl," "aryl C₁-C₆ alkyl", "heteroaryl C₁-C₆ alkyl," "aryl C₂-C₆ alkenyl," "heteroaryl C₂-C₆ alkenyl," "aryl C₂-C₆ alkynyl," "heteroaryl C₂-C₆ alkynyl," "C₃-C₈-cycloalkyl C₁-C₆ alkyl," or "heterocycloalkyl C₁-C₆ alkyl" and the like.

20 The term "sulfonyloxy C₁-C₆ alkyl" refers to alkyl groups having a sulfonyloxy substituent, including 2-(methylsulfonyloxy)ethyl and the like.

25 The term "sulfonyl" refers to group "-SO₂-R" wherein R is selected from "aryl," "heteroaryl," "C₁-C₆ alkyl," "C₁-C₆ alkyl" substituted with halogens, e.g., an -SO₂-CF₃ group, "C₂-C₆ alkenyl," "C₂-C₆ alkynyl," "C₃-C₈-cycloalkyl," "heterocycloalkyl," "aryl," "heteroaryl," "aryl C₁-C₆ alkyl", "heteroaryl C₁-C₆ alkyl," "aryl C₂-C₆ alkenyl," "heteroaryl C₂-C₆ alkenyl," "aryl C₂-C₆ alkynyl," "heteroaryl C₂-C₆ alkynyl," "C₃-C₈-cycloalkyl C₁-C₆ alkyl," or "heterocycloalkyl C₁-C₆ alkyl".

The term "sulfonyl C₁-C₆ alkyl" refers to alkyl groups having a sulfonyl substituent, including 2-(methylsulfonyl)ethyl and the like.

30 The term "sulfinyl" refers to a group "-S(O)-R" wherein R is selected from "C₁-C₆ alkyl," "C₁-C₆ alkyl" substituted with halogens, e.g., a -SO-CF₃ group, "C₂-C₆ alkenyl," "C₂-C₆ alkynyl," "C₃-C₈-cycloalkyl," "heterocycloalkyl," "aryl," "heteroaryl," "aryl C₁-C₆ alkyl", "heteroaryl C₁-C₆ alkyl," "aryl C₂-C₆ alkenyl," "heteroaryl C₂-C₆ alkenyl,"

“aryl C₂-C₆ alkynyl,” “heteroaryl C₂-C₆ alkynyl,” “C₃-C₈-cycloalkyl C₁-C₆ alkyl,” or “heterocycloalkyl C₁-C₆ alkyl”.

The term “sulfinyl C₁-C₆ alkyl” refers to alkyl groups having a sulfinyl substituent, including 2-(methylsulfinyl)ethyl and the like.

5 The term “sulfanyl” refers to groups –S-R where R includes H, halogens, e.g. a -SF₅ group, optionally substituted “C₁-C₆ alkyl,” in particular “C₁-C₆ alkyl” substituted with halogens, e.g., a –S-CF₃ group, “C₂-C₆ alkenyl,” “C₂-C₆ alkynyl,” “C₃-C₈-cycloalkyl,” “heterocycloalkyl,” “aryl,” “heteroaryl,” “aryl C₁-C₆ alkyl”, “heteroaryl C₁-C₆ alkyl,” “aryl C₂-C₆ alkenyl,” “heteroaryl C₂-C₆ alkenyl,” “aryl C₂-C₆ alkynyl,”

10 “alkynylheteroaryl,” “C₃-C₈-cycloalkyl C₁-C₆ alkyl,” or “heterocycloalkyl C₁-C₆ alkyl”.

The term “sulfanyl C₁-C₆ alkyl” refers to C₁-C₅-alkyl groups having a sulfanyl substituent, including 2-(ethylsulfanyl)ethyl and the like.

The term “sulfonylamino” refers to a group –NRSO₂-R’ where R and R’ are independently “C₁-C₆ alkyl,” “C₂-C₆ alkenyl,” “C₂-C₆ alkynyl,” “C₃-C₈-cycloalkyl,” “heterocycloalkyl,” “aryl,” “heteroaryl,” “aryl C₁-C₆ alkyl”, “heteroaryl C₁-C₆ alkyl,” “aryl C₂-C₆ alkenyl,” “heteroaryl C₂-C₆ alkenyl,” “aryl C₂-C₆ alkynyl,” “heteroaryl C₂-C₆ alkynyl,” “C₃-C₈-cycloalkyl C₁-C₆ alkyl,” or “heterocycloalkyl C₁-C₆ alkyl”.

The term “sulfonylamino C₁-C₆ alkyl” refers to alkyl groups having a sulfonylamino substituent, including 2-(ethylsulfonylamino)ethyl and the like.

20 The term "aminosulfonyl" refers to a group –SO₂-NRR' where R and R' are independently H, “C₁-C₆ alkyl,” “C₂-C₆ alkenyl,” “C₂-C₆ alkynyl,” “C₃-C₈-cycloalkyl,” “heterocycloalkyl,” “aryl,” “heteroaryl,” “aryl C₁-C₆ alkyl”, “heteroaryl C₁-C₆ alkyl,” “aryl C₂-C₆ alkenyl,” “heteroaryl C₂-C₆ alkenyl,” “aryl C₂-C₆ alkynyl,” “heteroaryl C₂-C₆ alkynyl,” “C₃-C₈-cycloalkyl C₁-C₆ alkyl,” or “heterocycloalkyl C₁-C₆ alkyl”, and where R and R', together with the nitrogen atom to which they are attached, can optionally form a 3-8-membered heterocycloalkyl ring. Aminosulfonyl groups include cyclohexylaminosulfonyl, piperidinylsulfonyl and the like.

The term “aminosulfonyl C₁-C₆ alkyl” refers to C₁-C₆ alkyl groups having an aminosulfonyl substituent, including 2-(cyclohexylaminosulfonyl)ethyl and the like.

30 Unless otherwise constrained by the definition of the individual substituent, the term “substituted” refers to groups substituted with from 1 to 5 substituents selected from the group consisting of “C₁-C₆ alkyl,” “C₂-C₆ alkenyl,” “C₂-C₆ alkynyl,” “C₃-C₈-

cycloalkyl," "heterocycloalkyl," "C₁-C₆ alkyl aryl," "C₁-C₆ alkyl heteroaryl," "C₁-C₆ alkyl C₃-C₈-cycloalkyl," "C₁-C₆ alkyl heterocycloalkyl," "acyl", "amino," "amide", "aminosulfonyl," "ammonium," "acyl amino," "aminocarbonyl," "aryl," "heteroaryl," "sulfinyl," "sulfonyl," "sulphonamide", "alkoxy," "alkoxy carbonyl," "carbamate," 5 "sulfanyl," "halogen," trihalomethyl, cyano, hydroxy, mercapto, nitro, and the like.

In a particular embodiment, the term optionally substituted "C₁-C₆ alkyl" includes optionally substituted halogenated "C₁-C₆ alkyl" such as fluorinated "C₁-C₆ alkyl" (e.g. -CF₃, -CF₃CH₂ or -CF₃CF₂).

The term "pharmaceutically acceptable salts or complexes" refers to salts or complexes 10 of the compounds according to the invention. Examples of such salts include, but are not restricted, to base addition salts formed by reaction of aminopyrazine derivatives of the invention with organic or inorganic bases such as hydroxide, carbonate or bicarbonate of a metal cation such as those selected in the group consisting of alkali metals (sodium, potassium or lithium), alkaline earth metals (e.g. calcium or 15 magnesium).

Are also comprised salts which are formed from acid addition salts formed with inorganic acids (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), as well as salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, fumaric acid, maleic acid, 20 ascorbic acid, benzoic acid, tannic acid, palmoic acid, alginic acid, polyglutamic acid, naphthalene sulfonic acid, naphthalene disulfonic acid, and poly-galacturonic acid.

"Pharmaceutically active derivative" refers to any compound that upon administration 25 to the recipient, is capable of providing directly or indirectly, the activity disclosed herein. The term "indirectly" also encompasses prodrugs which may be converted to the active form of the drug via endogenous enzymes or metabolism. The prodrug is a derivative of the compounds according to the invention and presenting anti-malarial activity that has a chemically or metabolically decomposable group, and a compound that may be converted into a pharmaceutically active compound according to the invention *in vivo* by solvolysis under physiological conditions. The prodrug is converted 30 into a compound according to the present invention by a reaction with an enzyme, gastric acid or the like under a physiological condition in the living body, e.g. by oxidation, reduction, hydrolysis or the like, each of which is carried out enzymatically.

These compounds can be produced from compounds of the present invention according to well-known methods.

The term "indirectly" also encompasses metabolites of compounds according to the invention.

5 The term "metabolite" refers to all molecules derived from any of the compounds according to the present invention in a cell or organism, preferably mammal.

In the context of the present invention are encompassed pharmaceutically acceptable salts, complexes, hydrates, solvates, or polymorphs, tautomers, geometrical isomers, optically active forms and pharmaceutically active derivatives of compounds of the 10 invention. Unless stated to the contrary, the present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof. Mixtures of stereoisomers, as well as isolated specific stereoisomers, are also included. During the course of the synthetic procedures used to prepare such 15 compounds, or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers. Many organic compounds exist in optically active forms having the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about 20 its chiral center(s).

The term "malaria" includes disease and conditions related to an infection by *Plasmodium*.

As used herein, "treatment" and "treating" and the like generally mean obtaining a 25 desired pharmacological and physiological effect. The effect may be prophylactic in terms of preventing or partially preventing a disease, symptom or condition thereof and/or may be therapeutic in terms of a partial or complete cure of a disease, condition, symptom or adverse effect attributed to the disease. The term "treatment" as used herein 30 covers any treatment of a disease in a mammal, particularly a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; or relieving the disease, i.e., causing regression of the disease and/or its symptoms or conditions.

The term "effective amount" includes "prophylaxis-effective amount" as well as "treatment-effective amount".

The term "prophylaxis-effective amount" refers to a concentration of compound of this invention that is effective in inhibiting, decreasing the likelihood of the disease by malarial parasites, or preventing malarial infection or preventing the delayed onset of the disease by malarial parasites, when administered before infection, i.e. before, during and/or slightly after the exposure period to malarial parasites.

The term "prophylaxis" includes causal prophylaxis, i.e. antimalarial activity comprising preventing the pre-erythrocytic development of the parasite, suppressive

prophylaxis, i.e. antimalarial activity comprising suppressing the development of the blood stage infection and terminal prophylaxis, i.e. antimalarial activity comprising suppressing the development of intra-hepatic stage infection. This term includes primary prophylaxis (i.e. preventing initial infection) where the antimalarial compound is administered before, during and/or after the exposure period to malarial parasites and terminal prophylaxis (i.e. to prevent relapses or delayed onset of clinical symptoms of malaria) when the antimalarial compound is administered towards the end of and/or slightly after the exposure period to malarial parasites but before the clinical symptoms.


Typically, against *P. falciparum* infections, suppressive prophylaxis is used whereas against *P. vivax* or a combination of *P. falciparum* and *P. vivax*, terminal prophylaxis is used.

Likewise, the term "treatment-effective amount" refers to a concentration of compound that is effective in treating malaria infection, e.g. leads to a reduction in parasite numbers in blood following microscopic examination when administered after infection has occurred.

The term "subject" as used herein refers to mammals. For examples, mammals contemplated by the present invention include humans and the like.

Compounds

According to one embodiment, is a provided aminopyrazine derivative according to Formula (I):



(I)

wherein X is CR¹ or N; Y is selected from CF₃, -C(O)-NR³R⁴; O-R⁶; SO₂-R⁶; R¹ is selected from H and halogen such as F; R² is selected from SO₂-R⁵ and -C(O)-R¹⁰; R³ and R⁴ are independently selected from H and optionally substituted C₁-C₆ alkyl such as optionally substituted methyl (e.g. methyl); R⁵ is selected from -NR⁷R⁸ and R⁹; R⁶ is optionally substituted C₁-C₆ alkyl such as optionally substituted methyl (e.g. methyl); R⁷ and R⁸ are independently selected from H and optionally substituted C₁-C₆ alkyl such as optionally substituted methyl (e.g. methyl); R⁹ is optionally substituted C₁-C₆ alkyl such as C₁-C₆ alkyl optionally substituted by C₁-C₆ alkyl or by C₃-C₈ cycloalkyl, for example optionally substituted cyclopropyl, optionally substituted methyl (e.g. methyl, methyl cyclopropyl), optionally substituted ethyl (e.g. ethyl), optionally substituted propyl (e.g. isopropyl) or optionally substituted C₃-C₈ cycloalkyl; R¹⁰ is -NR¹¹R¹²; R¹¹ and R¹² are independently selected from H and optionally substituted C₁-C₆ alkyl or NR¹¹R¹² form together an optionally substituted heterocycloalkyl such as optionally substituted piperazine (e.g. piperazine optionally substituted with C₁-C₆ alkyl like piperazin-1-yl, 4-methyl piperazin-1-yl or 4-t-butyl piperazin-1-yl), optionally substituted morpholinyl (e.g. morpholino), optionally substituted diazepan (e.g. diazepan optionally substituted with C₁-C₆ alkyl like 1,4 diazepan or 4-methyl 1,4 diazepan), optionally substituted pyrrolidin (e.g. pyrrolidin optionally substituted by amino or hydroxy like 3-hydroxy pyrrolidin-1-yl or 3-amino pyrrolidin-1-yl), optionally substituted piperidine (e.g. piperidine optionally substituted by hydroxy or amino like 4-hydroxy piperidin-1-yl, 4-amino piperidin-1-yl); as well as pharmaceutically acceptable salts, complexes, hydrates, solvates, or polymorphs, tautomers, geometrical isomers, 25 optically active forms and pharmaceutically active derivative thereof.

In a particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein X is N.

In a particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein X is N and Y is selected from CF₃ and O-R⁶.

In another particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein X is CR¹.

5 In another particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R¹ is H.

In another particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R¹ is halogen, in particular fluoro.

10 In another particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein Y is CF₃.

In another particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein Y is -C(O)-NHR³.

In another particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R³ is H.

15 In another particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R⁴ is optionally substituted C₁-C₆ alkyl such as optionally substituted methyl (e.g. methyl).

In another particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein Y is SO₂-R⁶.

20 In another particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R⁶ is optionally substituted methyl (e.g. methyl).

In a further particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein X is CR¹, R¹ is H and Y is selected from C(O)-NHR³ and SO₂-R⁶.

25 In a further particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein X is CR¹, R¹ is H and Y is CF₃.

In another particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R² is in para position of the phenyl ring.

In another particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R² is SO₂-R⁵.

5 In a further particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R⁵ is -NR⁷R⁸.

In a further particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R⁷ is H.

10 In a further particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R⁸ is H.

In a further particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R⁸ is optionally substituted C₁-C₆ alkyl such as optionally substituted methyl (e.g. methyl).

15 In another further particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R⁵ is R⁹.

In another further particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R⁹ is optionally substituted C₁-C₆ alkyl.

20 In another further particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R⁹ is C₁-C₆ alkyl optionally substituted by C₁-C₆ alkyl or by C₃-C₈ cycloalkyl.

In another further particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R⁹ is optionally substituted C₃-C₈ cycloalkyl.

25 In another further particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R⁹ is optionally substituted methyl (e.g.

methyl), optionally substituted ethyl (e.g. ethyl) and optionally substituted propyl (e.g. isopropyl).

In another particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R² is -C(O)-R¹⁰.

5 In another particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R¹¹ and R¹² are independently selected from H and optionally substituted C₁-C₆ alkyl.

In another particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein NR¹¹R¹² form together an optionally substituted 10 heterocycloalkyl such as optionally substituted piperazine (e.g. piperazine optionally substituted with C₁-C₆ alkyl like piperazin-1-yl, 4-methyl piperazin-1-yl or 4-t-butyl piperazin-1-yl), optionally substituted morpholinyl (e.g. morpholino), optionally substituted diazepan (e.g. diazepan optionally substituted with C₁-C₆ alkyl like 1,4 diazepan or 4-methyl 1,4 diazepan), optionally substituted pyrrolidin (e.g. pyrrolidin 15 optionally substituted by amino or hydroxy like 3-hydroxy pyrrolidin-1-yl, 3-amino pyrrolidin-1-yl), optionally substituted piperidine (e.g. piperidine optionally substituted by hydroxy or amino like 4-hydroxy piperidin-1-yl, 4-amino piperidin-1-yl).

In another particular embodiment, the invention provides an aminopyrazine derivative according to the invention wherein R² is -C(O)-NR¹¹R¹² and NR¹¹R¹² form together an 20 optionally substituted pyrrolidine.

In a particular embodiment is provided an aminopyrazine derivative selected from the following group:

3-(6-methoxypyridin-3-yl)-5-(4-(methylsulfonyl)phenyl)pyrazin-2-amine;

5-(4-(methylsulfonyl)phenyl)-3-(4-(trifluoromethyl)phenyl)pyrazin-2-amine

25 5-(4-(methylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine;

4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)benzamide;

4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)benzamide;

(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-methylpiperazin-1-yl) 25 methanone;

(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-methylpiperazin-1-yl)methanone;

(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(piperazin-1-yl)methanone;

5 (4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(piperazin-1-yl)methanone;

(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(morpholino)methanone;

(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(morpholino)methanone;

10 (4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-methyl-1,4-diazepan-1-yl)methanone;

4-(5-amino-6-(3-fluoro-4-(trifluoromethyl)phenyl)pyrazin-2-yl)benzamide;

4-(5-amino-6-(4-(methylsulfonyl)phenyl)pyrazin-2-yl)benzamide;

4,4'-(3-aminopyrazine-2,6-diyl)dibenzamide;

15 4-(3-amino-6-(4-carbamoylphenyl)pyrazin-2-yl)-N-methylbenzamide;

4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)-N-methylbenzene sulfonamide;

5-(4-(ethylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine;

5-(4-(isopropylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine;

20 (4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-(tert-butyl)piperazin-1-yl)methanone;

(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(3-hydroxypyrrolidin-1-yl)methanone;

(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-hydroxy

25 piperidin-1-yl)methanone;

(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-hydroxypiperidin-1-yl)methanone;

(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-(tert-butyl)piperazin-1-yl)methanone;

30 (4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-methyl-1,4-diazepan-1-yl)methanone;

(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(1,4-diazepan-1-yl) methanone;

(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(1,4-diazepan-1-yl) methanone;

5 (4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(3-aminopyrrolidin-1-yl)methanone;

(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(3-aminopyrrolidin-1-yl) methanone;

(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(3-hydroxy 10 pyrrolidin-1-yl)methanone;

(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-amino cyclohexyl) methanone;

(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-aminocyclohexyl) methanone;

15 5-(4-(cyclopropylmethylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine; and

5-(4-(cyclopropylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine; as well as pharmaceutically acceptable salts, complexes, hydrates, solvates, or polymorphs, tautomers, geometrical isomers, optically active forms and 20 pharmaceutically active derivative thereof.

In another particular embodiment is provided the aminopyrazine derivative (4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(3-hydroxypyrrrolidin-1-yl)methanone, in particular its (S)-(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(3-hydroxypyrrrolidin-1-yl)methanone enantiomer.

25 In another particular embodiment is provided the aminopyrazine derivative (4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(3-hydroxypyrrrolidin-1-yl) methanone, in particular its (R)-(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(3-hydroxypyrrrolidin-1-yl)methanone enantiomer.

The aminopyrazine derivatives used in the manufacture of a medicament for the prevention or treatment of malaria, are capable of killing and/or inhibiting malaria parasite replication.

Compositions

5 The invention provides pharmaceutical compositions useful for the prophylaxis or treatment of malaria. The invention further provides methods for treating a mammalian patient, and most preferably a human patient, who is suffering from malaria.

In another particular embodiment, is provided a pharmaceutical formulation containing at least one derivative according the invention and a pharmaceutically acceptable 10 carrier, diluent or excipient thereof.

In another particular embodiment, is provided a pharmaceutical formulation comprising an aminopyrazine according to Formula (I) and an antimalarial agent as defined in the detailed description.

Pharmaceutical compositions of the invention can contain one or more compound(s) of 15 the invention in any form described herein. Compositions of this invention may further comprise one or more pharmaceutically acceptable additional ingredient(s), such as alum, stabilizers, antimicrobial agents, buffers, coloring agents, flavoring agents, adjuvants, and the like.

The compounds of the invention, together with a conventionally employed adjuvant, 20 carrier, diluent or excipient may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit 25 dosage forms thereof may comprise ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended dosage range to be employed. Compositions according to the invention are preferably oral.

Compositions of this invention may be liquid formulations, including, but not limited to, aqueous or oily suspensions, solutions, emulsions, syrups, and elixirs. Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like. The 5 compositions may also be formulated as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain additives, including, but not limited to, suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. Suspending agents include, but are not limited to, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, 10 carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats. Emulsifying agents include, but are not limited to, lecithin, sorbitan monooleate, and acacia. Non-aqueous vehicles include, but are not limited to, edible oils, almond oil, fractionated coconut oil, oily esters, propylene glycol, and ethyl alcohol. Preservatives include, but are not limited to, methyl or propyl p-hydroxybenzoate and sorbic acid. 15 Further materials as well as processing techniques and the like are set out in *Part 5 of Remington's Pharmaceutical Sciences, 21st Edition, 2005, University of the Sciences in Philadelphia, Lippincott Williams & Wilkins*, which is incorporated herein by reference. Solid compositions of this invention may be in the form of tablets or lozenges formulated in a conventional manner. For example, tablets and capsules for oral 20 administration may contain conventional excipients including, but not limited to, binding agents, fillers, lubricants, disintegrants and wetting agents. Binding agents include, but are not limited to, syrup, accacia, gelatin, sorbitol, tragacanth, mucilage of starch and polyvinylpyrrolidone. Fillers include, but are not limited to, lactose, sugar, microcrystalline cellulose, maizestarch, calcium phosphate, and sorbitol. Lubricants include, but are not limited to, magnesium stearate, stearic acid, talc, polyethylene 25 glycol, and silica. Disintegrants include, but are not limited to, potato starch and sodium starch glycollate. Wetting agents include, but are not limited to, sodium lauryl sulfate. Tablets may be coated according to methods well known in the art.

Injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art. 30

Compositions of this invention may also be formulated as suppositories, which may contain suppository bases including, but not limited to, cocoa butter or glycerides.

Compositions of this invention may also be formulated for inhalation, which may be in a form including, but not limited to, a solution, suspension, or emulsion that may be administered as a dry powder or in the form of an aerosol using a propellant, such as dichlorodifluoromethane or trichlorofluoromethane. Compositions of this invention may 5 also be formulated transdermal formulations comprising aqueous or non-aqueous vehicles including, but not limited to, creams, ointments, lotions, pastes, medicated plaster, patch, or membrane.

Compositions of this invention may also be formulated for parenteral administration, including, but not limited to, by injection or continuous infusion. Formulations for 10 injection may be in the form of suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents including, but not limited to, suspending, stabilizing, and dispersing agents. The composition may also be provided in a powder form for reconstitution with a suitable vehicle including, but not limited to, sterile, pyrogen-free water.

15 Compositions of this invention may also be formulated as a depot preparation, which may be administered by implantation or by intramuscular injection. The compositions may be formulated with suitable polymeric or hydrophobic materials (as an emulsion in an acceptable oil, for example), ion exchange resins, or as sparingly soluble derivatives (as a sparingly soluble salt, for example).

20 Compositions of this invention may also be formulated as a liposome preparation. The liposome preparation can comprise liposomes which penetrate the cells of interest or the *stratum corneum*, and fuse with the cell membrane, resulting in delivery of the contents of the liposome into the cell. Other suitable formulations can employ niosomes. Niosomes are lipid vesicles similar to liposomes, with membranes consisting largely of 25 non-ionic lipids, some forms of which are effective for transporting compounds across the *stratum corneum*.

The compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can also be found in the incorporated materials in *Remington's* 30 *Pharmaceutical Sciences*.

Mode of administration

Compositions of this invention may be administered in any manner, including, but not limited to, orally, parenterally, sublingually, transdermally, vaginally, rectally, transmucosally, topically, via inhalation, via buccal or intranasal administration, or combinations thereof. Parenteral administration includes, but is not limited to, intravenous, intra-arterial, intra-peritoneal, subcutaneous, intramuscular, intra-thechal, and intra-articular. The compositions of this invention may also be administered in the form of an implant, which allows slow release of the compositions as well as a slow controlled i.v. infusion. In a preferred embodiment, aminopyrazine derivatives according to the invention are administered orally.

This invention is further illustrated by the following examples that are not intended to limit the scope of the invention in any way.

The dosage administered, as single or multiple doses, to an individual will vary depending upon a variety of factors, including pharmacokinetic properties, patient conditions and characteristics (sex, age, body weight, health, size), extent of symptoms, concurrent treatments, frequency of treatment and the effect desired.

Combination

According to the invention, the aminopyrazine derivatives of the invention and pharmaceutical formulations thereof can be administered alone or in combination with a co-agent useful in the treatment of malaria, such as substances useful in the treatment and/or prevention of malaria e.g. for example a co-agent including, but not limited to, artemisinin or an artemisinin derivative (such as artemether or dihydroartemisinin), chloroquine, mefloquine, quinine, atovaquone/proguanil, doxycycline, hydroxychloroquine, halofantrine, pyronaridine, lumefantrine, pyrimethamine-sulfadoxine and piperaquine.

Further co-agent useful in the context of the invention are selected from quinacrine, chloroquine, primaquine, doxycycline, atovaquone, proguanil hydrochloride, ferroquine, tafenoquine, arterolane, Spiro[3H-indole-3,1'-[1H]pyrido[3,4-b]indol]-2-(1H)-one (CAS Registry Number: 1193314-23-6), 5,7'-dichloro-6'-fluoro-2',3',4',9'-tetrahydro-3'-methyl-,(1'R,3'S)-], Sulfur, [4-[[2-(1,1-difluoroethyl)-5-methyl[1,2,4]

triazolo[1,5-a]pyrimidin-7-yl]amino]phenyl] pentafluoro-] (CAS Registry Number: 1282041-94-4), Morpholine, and 4-[2-(4-cis-dispiro[cyclohexane-1,3'-[1,2,4]trioxolane-5',2"-tricyclo [3.3.1.13,7]decan]-4-ylphenoxy)ethyl]-] (CAS Registry Number: 1029939-86-3).

5 The invention encompasses the administration of an aminopyrazine derivative according to the invention or of a pharmaceutical formulation thereof, wherein the aminopyrazine derivatives or the pharmaceutical formulation thereof is administered to an individual prior to, simultaneously or sequentially with other therapeutic regimens or co-agents useful in the treatment of malaria (e.g. multiple drug regimens), in an
10 effective amount. Aminopyrazine derivatives or the pharmaceutical formulations thereof that are administered simultaneously with said co-agents can be administered in the same or different composition(s) and by the same or different route(s) of administration.

Patients

15 In an embodiment, patients according to the invention are patients suffering from malaria.


In another embodiment, patients according to the invention are patients with a high risk of being infected by *Plasmodium*.

20 In another embodiment, patients according to the invention are patients with a high risk of being infected by *Plasmodium falciparum*.

In another embodiment, patients according to the invention are patients with a high risk of being infected by *Plasmodium vivax*.

Use according to the invention

25 In one embodiment, the invention provides a use of an aminopyrazine derivative according to Formula (I):



(I)

wherein X is CR¹ or N; Y is selected from CF₃, -C(O)-NR³R⁴; O-R⁶; SO₂-R⁶; R¹ is selected from H and halogen; R² is selected from SO₂-R⁵ and -C(O)-R¹⁰; R³ and R⁴ are independently selected from H and optionally substituted C₁-C₆ alkyl; R⁵ is selected from -NR⁷R⁸ and R⁹; R⁶ is optionally substituted C₁-C₆ alkyl; R⁷ and R⁸ are independently selected from H and optionally substituted C₁-C₆ alkyl; R⁹ is optionally substituted C₁-C₆ alkyl and optionally substituted C₃-C₈ cycloalkyl; R¹⁰ is -NR¹¹R¹²; R¹¹ and R¹² are independently selected from H and optionally substituted C₁-C₆ alkyl or NR¹¹R¹² form together an optionally substituted heterocycloalkyl; as well as pharmaceutically acceptable salts, complexes, hydrates, solvates, or polymorphs, tautomers, geometrical isomers, optically active forms and pharmaceutically active derivative thereof for the preparation of a pharmaceutical composition for the treatment or prophylaxis of malaria.


In another embodiment, the invention provides a method for preventing or treating malaria in a patient. The method comprises administering an effective amount of an aminopyrazine derivative according to the invention, or a pharmaceutically acceptable salt or a pharmaceutically active derivative thereof or a pharmaceutical formulation thereof in a patient in need thereof.

In another embodiment, the invention provides an aminopyrazine derivative according to the invention as well as pharmaceutically acceptable salts or a pharmaceutically active derivative thereof or a pharmaceutical formulation thereof, for use in the treatment or prophylaxis of malaria.

In another embodiment, the invention provides a use of an aminopyrazine derivative or a method according to the invention wherein the aminopyrazine derivative is to be administered in combination with a co-agent useful in the treatment of malaria.

In another embodiment, the invention provides a pharmaceutical composition comprising an aminopyrazine derivative according to the invention in combination with a co-agent useful in the treatment of malaria.

5 In another embodiment, the invention provides a process for the preparation of an aminopyrazine derivative according to the invention comprising the step of reacting a derivative according to Formula (v) with a boronic acid of Formula (vi) under Suzuki reaction conditions (*Miyaura et al., 1995, Chem. Rev., 95 (7), pp2457-2483*) to lead to a compound of Formula (I):



10 wherein A is


and D is:

, X, Y, R^1 and R^2 are as described herein.

In another embodiment, the invention provides an intermediate of Formula (v) wherein A is as defined herein.

15 In another further embodiment, the invention provides an intermediate of Formula (v), wherein the intermediate is 5-bromo-3-(6-methoxypyridin-3-yl)pyrazin-2-amine.

In another embodiment, the invention provides a process for the preparation of an aminopyrazine derivative according to the invention comprising the step of reacting a derivative according to Formula (viii) with a boronic acid of Formula (iv) under Suzuki reaction conditions (*Miyaura et al., 1995, supra*) to lead to a compound of Formula (I):




A, D, X, Y and R¹ as described herein.

In another embodiment, the invention provides an intermediate of Formula (viii) wherein D is as defined herein.

5 In another further embodiment, the invention provides an intermediate of Formula (viii),
wherein the intermediate is 3-bromo-5-(4-(methylsulfonyl) phenyl)pyrazin-2-amine.

In another further embodiment, the invention provides an intermediate of Formula (viii), wherein the intermediate is $(4\text{-}(5\text{-amino-6-bromopyrazin-2-yl)phenyl})(3\text{-hydroxypyrrolidin-1-yl)methanone}$.

In another embodiment, the invention provides a process for the preparation of an aminopyrazine derivative according to the invention comprising the step of reacting a derivative according to Formula (xix) in TFA to lead to a compound of Formula (V), i.e. a compound of Formula (I) wherein R² is in para of the phenyl ring and is R² is -C(O)-R¹⁰, NR¹¹R¹² form together a piperazine:



15 wherein A, X, Y and R¹ as described herein.

In another embodiment, the invention provides an intermediate of Formula (xix) wherein A is as defined herein.

In another embodiment, the invention provides an intermediate of Formula (xix) selected from the following group:

20 tert-butyl 4-(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)benzoyl)piperazine-1-carboxylate and tert-butyl 4-(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl) pyrazin-2-yl)benzoyl) piperazine-1-carboxylate.

In another embodiment, the invention provides a process for the preparation of an intermediate of formula (xv) comprising a step of reacting an intermediate of formula (xiv) in presence of N-methyl piperazine (e.g. as described in Scheme 3).

In another embodiment, the invention provides an intermediate of Formula (xiv).

5 In another embodiment, the invention provides an intermediate of Formula (xv).

In another embodiment, the invention provides a process for the preparation of an intermediate of Formula (xviii) comprising a step of reacting an intermediate of formula (xvii) in presence of N-bromosuccinimide (e.g. as described in Scheme 4).

In another embodiment, the invention provides an intermediate of Formula (xviii).

10 In another embodiment, the invention provides an intermediate of Formula (xvii).

In another embodiment, the invention provides a process for the preparation of an intermediate of Formula (xvii) comprising a step of reacting an intermediate of formula (xiv) in presence of N-Boc piperazine (e.g. as described in Scheme 4).

15 In another embodiment, the invention provides a process for the preparation of an intermediate of Formula (xxiv) comprising a step of reacting an intermediate of formula (xxiii) in presence of 1-methyl homo piperazine (e.g. as described in Scheme 5).

In another embodiment, the invention provides an intermediate of Formula (xxiv).

In another embodiment, the invention provides an intermediate of Formula (xxiii).

20 In another embodiment, the invention provides a process for the preparation of an intermediate of Formula (xxiii) comprising a step of reacting an intermediate of formula (xxii) in presence of lithium oxide (e.g. as described in Scheme 5).

In another embodiment, the invention provides an intermediate of Formula (xxii).

25 In another embodiment, the invention provides a process for the preparation of an intermediate of Formula (xxii) comprising a step of reacting an intermediate of formula (xiv) in presence of N-bromosuccinimide (e.g. as described in Scheme 5).

References cited herein are hereby incorporated by reference in their entirety. The present invention is not to be limited in scope by the specific embodiments described herein, which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

In the following the present invention shall be illustrated by means of some examples, which are not to be viewed as limiting the scope of the invention.

EXAMPLES

The following abbreviations refer respectively to the definitions below:

g (gram), **h** (hour), **mmol** (millimole), **RT** (room temperature), **DCM** (dichloromethane), **DMF** (N,N-Dimethylformamide), **DMSO** (Dimethyl Sulfoxide), **EDCI** (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide), **HOtB** (N-Hydroxybenzotriazole), **LC** (Liquid chromatography), **MS** (Mass Spectrometry), **MHz** (Megahertz), **NBS** (N-bromosuccinimide), **NMR** (Nuclear magnetic resonance), **TFA** (Trifluoroacetic acid), **THF** (Tetrahydrofuran), **TLC** (Thin layer chromatography), **UV** (Ultraviolet).

The compounds of invention have been named according to the IUPAC standards used in the program ChemDraw Ultra (Version 12.0).

The MS, NMR and IR data provided in the examples described below are obtained as followed: The MS, NMR and IR data provided in the examples described below are obtained as followed: Mass spectra: Waters ZQ API MS system + Binary HPLC system with Ultra Violet Diode Array Detector; H¹ NMR and C¹³ NMR spectra were recorded on either a Varian Mercury-300 (300 MHz) or Bruker Advance III 400 (400 MHz) with Ultra ShieldTM 400 Plus magnet spectrometer in CDCl₃ solution unless otherwise indicated and chemical shifts are reported as δ (ppm) down field from the solvent signal as internal standard for H¹ and C¹³ NMR. Infrared spectra were recorded on a Perkin-Elmer Paragon 1000 FT-IR spectrometer using DCM as solvent. TLC was performed on


Merck 60F₂₅₄ silica plates and visualised by UV light. The compounds were purified by wet flash chromatography using Merck Kieselgel 60 (particle size 70-230 mesh) silica under gravity. The compounds were purified by HPLC using a Hypersil BDS C18 column, 2 μ L injection volume, flow 0.7 mL/min; gradient: 10 – 70% B in 20 min, 70 – 5 100% B in 10 min, (hold 5 min), 100 – 10% in 3 min (hold 7 min) (Mobile phase A: 0.1% TFA in H₂O and Mobile phase B: Methanol) with PDA – maximum chromatogram (210 – 400 nm).

Example 1: Synthesis of compounds according to the invention:

The aminopyrazine derivatives can be prepared from readily available starting materials 10 using methods and procedures known from the skilled person. It will be appreciated that where typical or preferred experimental conditions (i.e. reaction temperatures, time, moles of reagents, solvents etc.) are given, other experimental conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by the person skilled 15 in the art, using routine optimisation procedures.

A general synthetic approach for obtaining compounds of Formula (I) is depicted in Scheme 1 below. Aminopyrazine derivatives according to Formula (I), whereby the substituents are as above defined, may be prepared in four steps, from custom made or commercially available aminopyrazines according to formula (i), 5-bromo-pyrazine-2- 20 amine according to formula (ii), 5-bromo-3-iodopyrazine-2-amine of formula (iii), or boronic acids of formulae (iv) or (vi) and substituted 5-bromopyrazine-2-amine derivatives according to formula (v), according to formula (iv), following the synthetic pathway as outlined in Scheme 1 below.

Scheme 1




To a solution of 2-aminopyrazine (i) (2 g, 21.02 mmol) in dry DCM (10 ml) was added NBS (3.78 g, 21.23 mmol) portion-wise under cold condition and the resulting mixture was allowed to stir at RT for 6h. 5 ml of water was added and the layers were separated. Aqueous layer was extracted with DCM (10 ml X 2). Combined organic layers were washed with Brine solution (5 ml), dried over anhydrous Na₂SO₄ and concentrated under vacuum. Crude material was purified by column chromatography over silica gel 230-400 mesh by using 18% of ethyl acetate in petroleum ether as an eluent to afford compound (ii) (1.98 g, 54.42%) as white solid.

To a solution of compound (ii) (1.98 g, 11.46 mmol) in DMSO (20 ml) was added iodine crystals (3.49 g, 13.75 mmol) at RT and the resulting mixture was heated to 100°C for 4 h and then stirred at RT for 12 h. Water (20 ml) was then added and the reaction mixture was extracted with ethyl acetate (60 ml X 4). Combined organic layers were washed with water (10 ml X 3), saturated sol. of sodium metabisulphite (5 ml X till Iodine color disappears), Brine solution (10 ml), dried over anhydrous Na₂SO₄ and concentrated under vacuum. The crude material was purified by column chromatography over silica gel 230-400 mesh by using ethyl acetate in petroleum ether as an eluent to yield compound (iii) (260 mg, 7.56%) as white solid.

To the solution of compound (iii) (355 mg, 1.18 mmol) in 1,4-dioxane (5 ml) was added a boronic acid of formula (iv) such as 6-methoxypyridin-3-yl boronic acid

(CombiBlocks 190 mg, 1.24 mmol) at RT and the reaction mixture was purged with N₂ gas for 30 minutes. Bis(triphenylphosphine)palladium(II)chloride (58 mg, 0.08 mmol) and 1 M aqueous solution of potassium carbonate (1.42 ml, pre-purged with N₂ gas) were added to the reaction mixture. The solution was heated to reflux for 16 h and then 5 cooled to RT, added Brine solution (5 ml) and extracted with ethyl acetate (10 ml X 4). Combined organic layers were dried over anhydrous Na₂SO₄ and concentrated. Crude material was purified by column chromatography over silica gel 230-400 mesh by using 1-2% MeOH in DCM as an eluent to yield compound (v) (150 mg, 45.18%) as solid. To the solution of compound (v) (240 mg, 0.85 mmol) in 1,4-dioxane (3 ml) was added a 10 boronic acid of formula (vi) such as 4-methylsulphonylphenylboronic acid (CombiBlocks) (187 mg, 0.93 mmol) at RT in a seal tube and the solution was purged with N₂ gas for 30 minutes. Bis(triphenylphosphine)palladium(II)chloride (41 mg, 0.059 mmol) and 1 M aqueous solution of potassium carbonate (1.02 ml, pre-purged with N₂ gas) were added to the reaction mixture. The resulting solution was heated to 15 110°C for 16h, cooled to RT, added Brine solution (3 ml) and extracted with Ethyl acetate (7 ml X 4). Combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under vacuum. Crude material was purified by column chromatography over silica gel 230-400 mesh by using 2-3% of MeOH in DCM as an eluent to yield to a compound of Formula (I) such as compound (1) (63.25 mg, 24.23%) as solid.



20


(1)

3-(6-methoxypyridin-3-yl)-5-(4-(methylsulfonyl)phenyl)pyrazin-2-amine; MS m/z [M⁺H]⁺: 357.2; 400 MHz, DMSO-d6: δ 8.70 (s, 1H), 8.60 (s, 1H), 8.26 (d, J = 8.20 Hz, 2H), 8.11 (d, J = 7.52 Hz, 1H), 7.97 (d, J = 8.12 Hz, 2H), 6.98 (d, J = 8.56 Hz, 1H), 6.71 (s, 1H), 3.94 (s, 3H), 3.24 (s, 3H).

25 Alternatively, compounds of Formula (I) wherein R² is SO₂-R⁵ and -C(O)-R¹⁰; R³ and R⁴ are independently selected from H and optionally substituted C₁-C₆ alkyl; R⁵ is

selected from $-\text{NR}^7\text{R}^8$ and R^9 ; R^6 is optionally substituted $\text{C}_1\text{-C}_6$ alkyl; R^7 and R^8 are independently selected from H and optionally substituted $\text{C}_1\text{-C}_6$ alkyl; R^9 is optionally substituted $\text{C}_1\text{-C}_6$ alkyl; R^{10} is $-\text{NR}^{11}\text{R}^{12}$; R^{11} and R^{12} are independently selected from H and optionally substituted $\text{C}_1\text{-C}_6$ alkyl or $\text{NR}^{11}\text{R}^{12}$ form together an optionally substituted heterocycloalkyl being an optionally substituted morpholino group can be obtained as depicted in Scheme 2 below:

Scheme 2



wherein A and D are as defined in Scheme 1.

10 To a solution of 5-bromo-pyrazine-2-amine according to formula (iii) (2.3 g, 13.21 mmol) in 1,4-dioxane (15 ml) was added a boronic acid of formula (vi) such as 4-methylsulfonylphenylboronic acid (CombiBlocks) (2.77 g, 13.87 mmol) at RT and the resulting mixture was purged with N_2 gas for 30 minutes. Bis(triphenylphosphine)palladium(II)chloride (463 mg, 0.66 mmol) and 1 M aqueous solution of potassium carbonate (15.84 ml, pre-purged with N_2 gas) were added to the reaction mixture. The reaction mixture was heated to reflux for 16 h, cooled to RT and concentrated under vacuum. 10 ml of water was added to the reaction mixture and extracted with ethyl acetate (15 ml X 4). Combined organic layers were washed with brine solution (10 ml), dried over anhydrous Na_2SO_4 and concentrated under vacuum.


15 The crude material was purified by column chromatography over silica gel 230-400 mesh by using 2-3% of MeOH in DCM as an eluent to yield to a 5-substituted pyrazine-2-amine of formula (vii) (2.5g, 75.91%) as white solid. To a solution of compound of formula (vii) (1.5 g, 4.0 mmol) in dry THF (30 ml) was added N-bromosuccinimide (1.58 g, 6.01 mmol) portion-wise at RT and heated to reflux for 30 minutes. Reaction mixture was cooled to RT, added 10 ml of water and extracted with ethyl acetate (30 ml X 3). Combined organic layers was washed with brine solution (20 ml), dried over anhydrous Na_2SO_4 and concentrated under vacuum. The crude material was purified by

20

25

column chromatography over silica gel 230-400 mesh by using 40% of ethyl acetate in petroleum ether as an eluent to yield to a 5-substituted-3-bromopyrazine-2-amine of formula (viii) (1.02g, 67.10%) as white solid.


To a suspension of compound (viii) (330 mg, 1.0 mmol) in 1, 4-dioxane (5 ml) was 5 added a boronic acid of formula (iv) such as 4-(trifluoromethyl)phenyl boronic acid (CombiBlocks (200 mg, 1.05 mmol) at RT and the resulting mixture was purged with N₂ gas for 30 minutes. Bis(triphenylphosphine)palladium(II)chloride (49 mg, 0.07 mmol) and 1 M aqueous solution of potassium carbonate (1.2 ml, pre-purged with N₂ gas) were added to the reaction mixture. The reaction mixture was heated to reflux for 10 16 h, cooled to RT and concentrated under vacuum. 5 ml of water was added to the reaction mixture and extracted with ethyl acetate (10 ml X 4). Combined organic layers were washed with brine solution (5 ml), dried over anhydrous Na₂SO₄ and concentrated under vacuum. The crude material was purified by preparative HPLC to yield compound of Formula (I) such as compound (2) (95 mg, 22.90%) as white solid.



15

(2)

5-(4-(methylsulfonyl)phenyl)-3-(4-(trifluoromethyl)phenyl)pyrazin-2-amine; MS m/z [M⁺H]⁺: 394.0; 400 MHz, DMSO-d6: δ 8.76 (s, 1H), 8.25 (d, J = 8.48 Hz, 2H), 8.02 (d, J = 8.12 Hz, 2H), 7.97 (d, J = 8.48 Hz, 2H), 7.88 (d, J = 8.20 Hz, 2H), 6.76 (s, 2H), 3.24 (s, 3H). Compound (3), i.e. 5-(4-(methylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine was prepared using 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester in step 3 which gave 0.243g (25.31%) yield as white solid.



(3)


MS m/z [M+H]+: 395.0; 400 MHz, DMSO-d6: δ 9.15 (d, J = 1.72 Hz, 1H), 8.83 (d, J = 9.56 Hz, 1H), 8.47 (dd, J = 1.80, 8.06 Hz, 1H), 8.28 (d, J = 8.64 Hz, 2H), 8.05 (d, J = 8.16 Hz, 1H), 7.97-8.00 (m, 2H), 6.94 (s, 2H), 3.25 (s, 3H).

Alternatively, compounds of Formula (I) wherein R² is -C(O)NR¹¹R¹² and R¹¹ and R¹² are independently selected from H and optionally substituted C₁-C₆ alkyl or when NR¹¹R¹² forms together an optionally substituted heterocycloalkyl being an optionally substituted morpholino group can be obtained as depicted in Scheme 2 as described below:

Compounds of Formula (I) wherein R² is -C(O)NR¹¹R¹² and R¹¹ and R¹² are independently selected from H and optionally substituted C₁-C₆ alkyl


To a solution of a 5-bromo-pyrazine-2-amine according to formula (ii) (2.3 g, 13.21 mmol) in 1,4-dioxane (15 ml) was added a boronic acid of formula (vi) such as 4-carbamoylphenylboronic acid (CombiBlocks) (2.29 g, 13.87 mmol) at RT and the resulting mixture was purged with N₂ gas for 30 minutes. Bis(triphenylphosphine) palladium(II)chloride (462 mg, 0.66 mmol) and 1 M aqueous solution of potassium carbonate (15.84 ml, pre-purged with N₂ gas) were added to the reaction mixture. The reaction mixture was heated to reflux for 16 h, cooled to RT and concentrated under vacuum. 10 ml of water was added to the reaction mixture. Precipitate solid was filtered, washed with cold water (2 ml X 3), DCM (3 ml X 3) and dried to get a 5-substituted pyrazine-2-amine of formula (vii) (2.0 g, 70.82%) as white solid. To a solution of compound (vii) (1g, 4.66 mmol) in dry 1, 4-dioxane (100 ml) was added N-bromosuccinimide (0.83 g, 4.66 mmol) portion-wise at RT and the solution was heated to 80°C for 4h. Reaction mixture was concentrated under *vacuum* and water was added (10 ml). Precipitate solid was filtered and dried. The crude solid was purified by column

chromatography over silica gel 230-400 mesh by using 2-3% of MeOH in DCM as an eluent to yield 5-substituted 3-bromopyrazine-2-amine of formula (viii) (0.4g, 29.23%) as white solid. To a suspension of intermediate (viii) (300 mg, 1.02 mmol) in 1, 4-dioxane (10 ml) was added a boronic acid of formula (iv) such as 4-(trifluoromethyl)phenyl boronic acid (CombiBlocks) (204 mg, 1.07 mmol) at RT and the resulting mixture was purged with N₂ gas for 30 minutes. Bis(triphenylphosphine)palladium(II)chloride (50 mg, 0.07mmol) and 1 M aqueous solution of potassium carbonate (1.22 ml, pre-purged with N₂ gas) were added to the reaction mixture. The reaction mixture was heated to reflux for 16 h, cooled to RT and concentrated under vacuum. 5 ml of water was added to the reaction mixture and extracted with ethyl acetate (10 ml X 4). Combined organic layers were washed with brine solution (5 ml), dried over anhydrous Na₂SO₄ and concentrated under vacuum. The crude solid was purified by column chromatography over silica gel 230-400 mesh by using 1.2-1.5% of MeOH in DCM as an eluent to yield to a compound of Formula (I) such as compound (4) (180 mg, 48.18%) as pale yellow solid.



(4)

4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)benzamide; MS m/z [M⁺H]⁺: 359.2; 400 MHz, DMSO-d6: δ 8.71 (s, 1H), 8.01-8.08 (m, 5H), 7.94 (d, J = 8.40 Hz, 2H), 7.87 (d, J = 8.24 Hz, 2H), 7.37 (s, 1H), 6.62 (s, 2H). Compound (5), i.e. 4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)benzamide was prepared using 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester in Step 3 which gave 0.450g (61.22%) yield as pale yellow solid.




(5)

MS m/z $[M^+H]^+$: 360.0; 400 MHz, DMSO-d6: δ 9.15 (d, J = 1.72 Hz, 1H), 8.75 (s, 1H), 8.47 (dd, J = 1.92, 8.06 Hz, 1H), 8.09 (d, J = 8.48 Hz, 2H), 8.01-8.04 (m, 2H), 7.95 (d, J = 8.52 Hz, 2H), 7.37 (s, 1H), 6.79 (s, 2H).

Compounds of Formula (I) wherein R^2 is $-C(O)NR^{11}R^{12}$ where $NR^{11}R^{12}$ forms together an optionally substituted heterocycloalkyl being an optionally substituted morpholino group


To the solution of a 5-bromo-pyrazine-2-amine according to formula (1.5 g, 8.62 mmol) in 1,4-dioxane (20 ml) was added a boronic acid of formula (vi) such as 4-(morpholine-4-carbonyl)phenylboronic acid (CombiBlocks) (2.046 g, 8.70 mmol) at RT and the resulting mixture was purged with N_2 gas for 30 minutes. Bis(triphenylphosphine)palladium (II)chloride (423 mg, 0.60 mmol) and 1 M aqueous solution of potassium carbonate (10.34 ml, pre-purged with N_2 gas) were added to the reaction mixture. The reaction mixture was heated to reflux for 16 h, cooled to RT and concentrated under vacuum. 5 ml of water was added to the reaction mixture and extracted with ethyl acetate (20 ml X 4). Combined organic layers were washed with brine solution (5 ml), dried over anhydrous Na_2SO_4 and concentrated under vacuum. The crude material was purified by column chromatography over silica gel 230-400 mesh by using 2% of MeOH in DCM as an eluent to yield a 5-substituted pyrazine-2-amine of formula (vii) (1.1 g, 44.88%) as pale yellow solid. To a suspension of a compound of formula (vii) (1.1 g, 3.86 mmol) in dry DCM (10 ml) was added N-bromosuccinimide (0.688 g, 3.86 mmol) portion-wise under cold condition and the resulting mixture was allowed to stir at RT for 30 minutes. To the reaction mixture was added 5 ml of water and the layers were separated. Aqueous layer was extracted with DCM (10 ml X 3). Combined organic layers were washed with brine solution (5 ml), dried over anhydrous Na_2SO_4 and concentrated under vacuum. The crude material was

purified by column chromatography over silica gel 230-400 mesh by using 3% of MeOH in DCM as an eluent to yield 5-a substituted 3-bromopyrazine-2-amine of formula (viii) (0.85g, 60.48%) as yellow solid. To a suspension of compound of formula (viii) (825 mg, 1.17 mmol) in 1, 4-dioxane (10 ml) was added a boronic acid of formula (iv) such as 4-(trifluoromethyl)phenyl boronic acid (CombiBlocks) (233 mg, 1.22 mmol) at RT and the resulting mixture was purged with N₂ gas for 30 minutes. Bis(triphenylphosphine)palladium(II)chloride (58 mg, 0.081 mmol) and 1 M aqueous solution of potassium carbonate (1.46 ml, pre-purged with N₂ gas) were added to the reaction mixture. The reaction mixture was heated to reflux for 16 h, cooled to RT and concentrated under vacuum. 5 ml of water was added to the reaction mixture and extracted with ethyl acetate (10 ml X 4). Combined organic layers were washed with brine solution (5 ml), dried over anhydrous Na₂SO₄ and concentrated under vacuum. The crude material was purified by column chromatography over silica gel 230-400 mesh by using 2% of MeOH in DCM as an eluent to yield to a compound of Formula (I) such as compound (11) (24 mg, 48.87%) as pale off white solid.



(11)

(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(morpholino)methanone; MS m/z [M⁺H]⁺: 429.1; 400 MHz, DMSO-d6: δ 8.67 (s, 1H), 8.02-8.08 (m, 4H), 7.87 (d, J = 8.28 Hz, 2H), 7.48 (d, J = 8.20 Hz, 2H), 6.61 (s, 2H), 3.63 (br, 8H). Compound (10), i.e. (4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl) (morpholino) methanone was prepared using 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester in step 4 which gave 0.261 g (51.95%) yield as yellow solid.




(10)

MS m/z [M⁺H]⁺: 430.2; 400 MHz, DMSO-d6: δ 9.15 (d, J = 1.72 Hz, 1H), 8.73 (s, 1H), 8.47 (dd, J = 1.80, 8.10 Hz, 1H), 8.03-8.09 (m, 3H), 7.49 (d, J = 8.40 Hz, 2H), 6.79 (s, 2H), 3.61 (br, 8H).

Alternatively, compounds of Formula (I) wherein R^2 is $-C(O)NR^{11}R^{12}$ and R^{11} and R^{12} are independently selected from H and optionally substituted C_1 - C_6 alkyl or when $NR^{11}R^{12}$ forms together an optionally substituted heterocycloalkyl being an optionally substituted 4-methyl piperazin-1-yl, 4-t-butyl piperazin-1-yl can be obtained as depicted in Scheme 3 below:

Scheme 3



Wherein A is as defined in Scheme 1.


To the solution of a 5-bromo-pyrazine-2-amine according to formula (ii) (8.5 g, 48.8 mmol) in 1,4-dioxane (75 ml) was added 4-carboxyphenylboronic acid (8.45 g, 51.2 mmol) at RT and the resulting mixture was purged with N_2 gas for 30 minutes. Bis(triphenylphosphine)palladium(II)chloride (1.71 g, 2.44 mmol) and 1M aqueous solution of potassium carbonate (58.51 ml, pre-purged with N_2 gas) were added to the reaction mixture. The reaction mixture was heated to reflux for 16h, cooled to RT and concentrated under vacuum. The crude material was purified by preparative HPLC to yield a novel carboxylic acid intermediate of formula (xiv) (5.37g, 51.43%) as solid. To a suspension of a carboxylic acid intermediate of formula (xiv) (1 g, 4.67 mmol) in dry DCM (10 ml) was added thionylchloride (1 ml) under cold condition and refluxed for 2 h. Reaction mixture was concentrated under vacuum in N_2 -atmosphere and added 10 ml of dry DCM. Reaction mixture was cooled to 0°C , added triethylamine (1.287 g, 12.72 mmol) followed by N-methylpiperazine (425 mg, 4.24 mmol) in DCM (3 ml) and allowed to stir at RT for 6 h. 5 ml of cold water was added to the reaction mixture and

the layers were separated. Aqueous layer was extracted with DCM (10 ml X 2). Combined organic layers was washed with brine solution (5 ml), dried over anhydrous Na_2SO_4 and concentrated under vacuum. The crude material was purified by column chromatography over silica gel 230-400 mesh by using 2-3% of MeOH in DCM as an eluent to yield to a novel ketone intermediate of formula (xv) (660 mg, 52.38%) as solid. To a solution of an amide intermediate of formula (xv) (1 g, 4.01 mmol) in dry 1, 4-dioxane (10 ml) was added N-bromosuccinimide (1.07 g, 6.02 mmol) portion-wise at RT and the resulting mixture was allowed to stir for 30 minutes. Reaction mixture was decanted and dried to yield crude intermediate of formula (xvi) (0.5 g) as gummy solid.

10 To the suspension of crude (xvi) (250 mg, 0.66 mmol) in 1, 4-dioxane (4 ml) was added a boronic acid of formula (iv) such as 4-(trifluoromethyl)phenyl boronic acid (CombiBlocks) (0.69 mmol) at RT and purged with N_2 gas for 30 minutes. Bis(triphenylphosphine)palladium(II)chloride (32 mg, 0.46 mmol) and 1 M aqueous solution of potassium carbonate (0.79 ml, pre-purged with N_2 gas) were added to the reaction mixture. The reaction mixture was heated to reflux for 16 h, cooled to RT and concentrated under vacuum. 3 ml of water was added to the reaction mixture and extracted with ethyl acetate (10 ml X 4). Combined organic layers was washed with brine solution (5 ml), dried over anhydrous Na_2SO_4 and concentrated under vacuum. The crude solid was purified by column chromatography over silica gel 230-400 mesh by using 2-3% of MeOH in DCM as an eluent to yield to a compound of Formula (I) such as a compound of Formula (iv) like for example compound (6) (20 mg, 6.87%) as solid.

15


20



(6)

25 (4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-methylpiperazin-1-yl) methanone; MS m/z $[\text{M}^+\text{H}]^+$: 442.2; 400 MHz, CDCl_3 : δ 8.55 (s, 1H), 7.98-8.04 (m, 4H), 7.82 (d, J = 8.00 Hz, 2H), 7.53 (d, J = 8.00 Hz, 2H), 4.89 (s, 2H), 3.74 (d, J = 125.20 Hz, 4H), 2.60 (bs, 4H), 2.41 (s, 3H). Compound (7), i.e. (4-(5-amino-6-(6-

(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-methylpiperazin-1-yl)methanone was prepared using 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester (CombiBlocks) in step 4 which gave 17.9 mg (6.16%) yield as solid.



5

(7)


MS m/z $[\text{M}^+\text{H}]^+$: 443.2; 400 MHz, CDCl_3 : δ 9.26 (d, $J = 1.60$ Hz, 1H), 8.60 (s, 1H), 8.40 (dd, $J = 1.60, 8.00$ Hz, 1H), 8.03 (d, $J = 8.00$ Hz, 2H), 7.88 (d, $J = 8.00$ Hz, 1H), 7.53 (d, $J = 8.40$ Hz, 2H), 4.90 (s, 2H), 3.90 (s, 2H), 3.58 (s, 2H), 2.61 (s, 2H), 2.47 (s, 2H), 2.42 (s, 3H).

10 Alternatively, compounds of Formula (I) wherein R^2 is $-\text{C}(\text{O})\text{NR}^{11}\text{R}^{12}$ and R^{11} and R^{12} are independently selected from H and optionally substituted $\text{C}_1\text{-C}_6$ alkyl or when $\text{NR}^{11}\text{R}^{12}$ forms together an optionally substituted heterocycloalkyl being an optionally substituted piperazin-1-yl can be obtained as depicted in Scheme 4 below:

15

20

Scheme 4




Wherein A is as defined in Scheme 1.

To the solution of a 5-bromo-pyrazine-2-amine according to formula (ii) (8.5 g, 48.8 mmol) in 1,4-dioxane (75 ml) was added 4-carboxyphenylboronic acid (CombiBlocks) (8.45 g, 51.2 mmol) at RT and the resulting mixture was purged with N_2 gas for 30 minutes. Bis(triphenylphosphine)palladium(II)chloride (1.71 g, 2.44 mmol) and 1 M aqueous solution of potassium carbonate (58.51 ml, pre-purged with N_2 gas) were added to the reaction mixture. The reaction mixture was heated to reflux for 16 h, cooled to RT and concentrated under vacuum. The crude material was purified by preparative HPLC to yield a carboxylic acid intermediate of formula (xiv) (5.37 g, 51.43%) as solid. To a solution of a carboxylic acid intermediate of formula (xiv) (2.93 g, 13.60 mmol) in dry DMF (15 ml) was added EDCI (3.54 g, 18.54 mmol), HOBr (0.166 g, 1.23 mmol) and triethyl amine (3.75 g, 37.09 mmol) at RT and the solution was allowed to stir for 30 minutes. To the reaction mixture was added N-Boc piperazine (Aldrich) (2.3 g, 12.36 mmol) at RT and the mixture was stirred for 2 h. 25 ml of water was added to the reaction mixture and extracted with ethyl acetate (25 ml X 4). Combined organic layers were concentrated under vacuum. To the crude material was added DCM:Petroleum.ether (100 ml, 95:5) and filtered to yield a novel amide intermediate of formula (xvii) (1.02 g, 21.51%) as yellow solid. To the solution of intermediate of

formula **(xvii)** (1 g, 2.60 mmol) in dry THF (25 ml) was added N-bromosuccinimide (0.696 g, 3.91 mmol) portion-wise at RT and the mixture was heated to reflux for 30 minutes. Reaction mixture was cooled to RT, added water (25 ml) and extracted with ethyl acetate (50 ml X 3). Combined organic layers were washed with brine solution (20 ml), dried over anhydrous Na_2SO_4 and concentrated under vacuum. To the crude solid was added DCM:Pet.ether (50 ml, 95:5) and filtered to yield to a novel intermediate **(xviii)** (1 g, 83.26%) as brown solid. To the suspension of intermediate **(xviii)** (400 mg, 0.86 mmol) in 1, 4-dioxane (10 ml) was added a boronic acid of formula **(iv)** such as 4-(trifluoromethyl)phenyl boronic acid (CombiBlocks) (0.90 mmol) at RT and the solution was purged with N_2 gas for 30 minutes. Bis(triphenylphosphine) palladium(II)chloride (42 mg, 0.06 mmol) and 1M aqueous solution of potassium carbonate (1.03 ml, pre-purged with N_2 gas) were added to the reaction mixture. The reaction mixture was heated to reflux for 16 h, cooled to RT and concentrated under vacuum. 5 ml of water was added to the reaction mixture and extracted with ethyl acetate (20 ml X 4). Combined organic layers was washed with brine solution (10 ml), dried over anhydrous Na_2SO_4 and concentrated under vacuum. The crude solid was purified by column chromatography over silica gel 230-400 mesh by using 50% of ethyl acetate in petroleum.ether as an eluent yield intermediate **(xix)** wherein A is para-trifluoromethyl phenyl (205 mg, 44.95%) as yellow solid.


Intermediate **(xix)** wherein A is para-trifluoromethyl pyridin was prepared using 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester in step 4 which gave 0.212g (46.69%) yield as solid.

To the solution of intermediate **(xix)** (200 mg, 0.37 mmol) in DCM (4 ml) was added TFA (0.58 ml, 7.58 mmol) under cold condition and the resulting mixture was allowed to stir at RT for 45 minutes. Reaction mixture was concentrated under vaccum and crude was washed with diethyl ether (1.5 ml X 4) and dried. Reaction mixture was dissolved in dry DCM:MeOH (10 ml, 9:1), added Amberlyst A21 (0.157 mg, 0.75 mmol) at RT and allowed to stir for 30 minutes. Reaction mixture was filtered, washed with DCM:MeOH (3 ml X 3, 9:1) and filtrate was concentrated under vacuum. Crude compound was triturated with Diethylether (1.5 ml X 5) and dried to yield to a compound of Formula (I), such as compound **(8)** (90 mg, 55.55%) as yellow solid.



(8)

(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(piperazin-1-yl)methanone; MS m/z $[M^+H]^+$: 428.2; 400 MHz, DMSO-d6: δ 8.68 (s, 1H), 8.03-8.08 (m, 4H), 7.88 (d, J = 8.08 Hz, 2H), 7.47 (d, J = 8.16 Hz, 2H), 6.62 (s, 2H), 3.55 (d, J = 25.40 Hz, 4H), 2.79 (s, 4H). Compound (9), i.e. (4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(piperazin-1-yl) methanone was prepared following the same protocol but using intermediate (xix) wherein A is para-trifluoromethyl pyridin which gave 0.132g (81.48%) yield as white solid.




10

(9)

MS m/z $[M^+H]^+$: 429.2; 400 MHz, DMSO-d6: δ 9.15 (s, 1H), 8.74 (s, 1H), 8.47 (d, J = 8.16 Hz, 1H), 8.10 (d, J = 8.32 Hz, 2H), 8.05 (d, J = 8.16 Hz, 1H), 7.52 (d, J = 8.36 Hz, 2H), 6.81 (s, 2H), 3.59 (bs, 4H), 3.04 (s, 4H).

15 Alternatively, compounds of Formula (I) wherein R^2 is $-C(O)NR^{11}R^{12}$ and R^{11} and R^{12} are independently selected from H and optionally substituted C_1-C_6 alkyl or when $NR^{11}R^{12}$ forms together an optionally substituted heterocycloalkyl being an optionally substituted diazepan (e.g. 1,4 diazepan, 4-methyl 1,4 diazepan), optionally substituted pyrrolidin (e.g. 3-hydroxy pyrrolidin-1-yl, 3-amino pyrrolidin-1-yl), optionally substituted piperidine (e.g. 4-hydroxy piperidin-1-yl, 4-amino piperidin-1-yl).can be obtained as depicted in Scheme 5 below:


Scheme 5



Wherein A is as defined in Scheme 1.

To the solution of a 5-bromo-pyrazine-2-amine according to formula (ii) (10 g, 57.47 mmol) in 1,4-dioxane (100 ml) was added 4-methoxycarbonylphenylboronic acid (11.377 g, 63.21 mmol) followed by potassium phosphate tribasic (14.638 g, 68.96 mmol) and water 68.96 ml at RT. Reaction mixture was purged with N₂ gas for 1h. Bis(triphenylphosphine)palladium(II)chloride (2.823 g, 4.02 mmol) was added to the reaction mixture. The reaction mixture was heated to reflux for 16h, cooled to RT and 5 concentrated under vacuum to remove dioxane. Solid was filtered, washed with water (20 ml X 3), dried and again washed with MeOH (10 ml X 4) and dried to afford compound a methyl carboxylate intermediate of formula (xiv) (12.035 g, 91.36%, 84% purity) as pale yellow solid. To a cold suspension of a methyl carboxylate intermediate of formula (xiv) (7.5 g, 32.71 mmol) in dry DCM (75 ml) was added N-bromosuccinimide (6.405 g, 35.99 mmol) portion-wise and the resulting mixture was 10 stirred at RT for 1h. To the reaction mixture was added 20 ml of water. The solution was extracted with DCM:MeOH (100 ml X 5). Combined organic layers were washed with brine solution (50 ml), dried over anhydrous Na₂SO₄ and concentrated under vacuum. Crude material was purified by column chromatography over silica gel 15 230-

400 mesh by using 24% of ethyl acetate and 4% of DCM in petroleum ether as an eluent to afford a novel intermediate of formula **(xxii)** 4.767g, 47.28%) as pale yellow solid. To a solution of compound an intermediate of formula **(xxii)** (4.76 g, 15.44 mmol) in THF (50 ml) was added lithium hydroxide [0.554 g, 23.17 mmol, in water (5 ml)] at 5 RT. The resulting mixture was stirred for 16 h and concentrated under vacuum. To the residue was added 10 ml of water and conc. HCl till acidic. Solid was filtered, washed with water (10 ml X 3), dried and again washed with DCM (10 ml X 3) and dried to get a novel intermediate compound of formula **(xxiii)** (4.102 g, 90.33%) as pale yellow solid. To a suspension of an intermediate compound of formula **(xxiii)** (600 mg, 2.04 10 mmol) in dry THF (12 ml) was added EDCI-HCl (469 mg, 72.44 mmol), HOEt (28 mg, 0.20 mmol) and triethyl amine (516 mg, 5.10 mmol) at RT under N₂ atmosphere and the resulting mixture was stirred for 1 h. 1-methylhomo piperazine (256 mg, 2.24 mmol) was then added at RT and the solution was stirred for 16 h. 20 ml of water was added to the reaction mixture and extraction was carried out with ethyl acetate (50 ml X 4). 15 Combined organic layers was washed with brine solution (20 ml), dried over anhydrous Na₂SO₄ and concentrated under vacuum. The crude material was purified by column chromatography over neutral alumina by using 12% of MeOH in DCM as an eluent to yield to a novel intermediate compound of formula **(xxiv)** (350 mg, 43.96%) as pale yellow solid. To a solution of compound intermediate compound of formula **(xxiv)** (350 20 mg, 0.89 mmol) in 1, 4-dioxane (5 ml) was added a boronic acid of formula **(vi)** such as 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester (CombiBlocks) (269 mg, 0.98 mmol) at RT and purged with N₂ gas for 30 minutes. Bis(triphenylphosphine) palladium(II)chloride (45 mg, 0.062 mmol) and 1 M aqueous solution of potassium carbonate (1.07 ml, 1.07 mmol, pre-purged with N₂ gas) were added to the reaction 25 mixture. The reaction mixture was heated to reflux for 16 h, cooled to RT and concentrated under vacuum. 3 ml of brine solution was added to the reaction mixture and extracted with ethyl acetate (10 ml X 4). Combined organic layers was dried over anhydrous Na₂SO₄ and concentrated under vacuum. The crude material was purified by column chromatography over silica gel 230-400 mesh by using 5-6% of MeOH in DCM 30 as an eluent to afford a compounds of Formula (I) such as compound **(12)** (250 mg, 61.12%) as pale yellow solid.



(12)

(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-methyl-1,4-diazepan-1-yl)methanone; MS m/z $[M^+H]^+$: 457.2; 400 MHz, DMSO-d6: δ 9.15 (s, 1H), 8.72 (s, 1H), 8.47 (d, J = 8.12 Hz, 1H), 8.03-8.08 (m, 3H), 7.45-7.47 (m, 2H), 6.77 (s, 2H), 3.61-3.67 (m, 2H), 3.40-3.43 (m, 2H), 2.70 (bs, 1H), 2.59 (bs, 2H), 2.27-2.35 (m, 3H), 1.88 (bs, 1H), 1.78 (bs, 1H).







If the above synthetic methods are not applicable to obtain aminopyrazine derivatives according to the invention and/or necessary intermediates, suitable methods of preparation known by a person skilled in the art should be used. In general, the synthesis pathways for any individual derivative will depend on the specific substituents of each molecule and upon the ready availability of intermediates necessary; again such factors being appreciated by those of ordinary skill in the art. For all the protection and deprotection methods, see *Philip J. Kocienski*, in "Protecting Groups", *Georg Thieme Verlag Stuttgart*, 2005 and *Theodora W. Greene and Peter G. M. Wuts* in "Protective Groups in Organic Synthesis", Wiley Interscience, 4th Edition 2006. Compounds of this invention can be isolated in association with solvent molecules by crystallization from evaporation of an appropriate solvent. The pharmaceutically acceptable acid addition salts of the aminopyrazine derivatives, may be prepared in a conventional manner. For example, a solution of the free base may be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent. Pharmaceutically acceptable base addition salts may be obtained in an analogous manner by treating a solution of an aminopyrazine derivative with a suitable base. Both types of salts may be formed or interconverted using ion-exchange resin techniques.

Example 2: Synthesis of further compounds of the invention





The following compounds listed in Table 1 below were prepared using an analogous procedure to procedure described in Example 1.

Table 1

| Compound | Chemical name | Structure | MS m/z [M+H] ⁺ |
|----------|--|-----------|------------------------------|
| 13 | 4-(5-amino-6-(3-fluoro-4-(trifluoromethyl)phenyl)pyrazin-2-yl)benzamide | | 376.1 |
| 14 | 4-(5-amino-6-(4-(methylsulfonyl)phenyl)pyrazin-2-yl)benzamide | | 367.9 |
| 15 | 4,4'-(3-aminopyrazine-2,6-diyl)dibenzamide | | 332.9 |
| 16 | 4-(3-amino-6-(4-carbamoylphenyl)pyrazin-2-yl)-N-methylbenzamide | | 347.1 |
| 17 | 4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)-N-methylbenzenesulfonamide | | 409.1 |

| Compound | Chemical name | Structure | MS m/z [M+H] ⁺ |
|----------|---|---|------------------------------|
| 18 | 5-(4-(ethylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine |  | 408.1 |
| 19 | 5-(4-(isopropylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine |  | 422.0 |
| 20 | (4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-tert-butylpiperazin-1-yl)methanone |  | 484.4 |
| 21 | (4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(3-hydroxypyrrolidin-1-yl)methanone |  | 429.2 |
| 22 | (4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-hydroxypiperidin-1-yl)methanone |  | 444.2 |
| 23 | (4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-hydroxypiperidin-1-yl)methanone |  | 443.2 |

| Compound | Chemical name | Structure | MS m/z [M+H] ⁺ |
|----------|--|-----------|------------------------------|
| 24 | (4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-(tert-butyl)piperazin-1-yl)methanone | | 485.5 |
| 25 | (4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-methyl-1,4-diazepan-1-yl)methanone | | 456.2 |
| 26 | (4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(1,4-diazepan-1-yl)methanone | | 443.0 |
| 27 | (4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(1,4-diazepan-1-yl)methanone | | 442.2 |
| 28 | (4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(3-aminopyrrolidin-1-yl)methanone | | 429.0 |
| 29 | (4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(3-aminopyrrolidin-1-yl)methanone | | 428.0 |

| Compound | Chemical name | Structure | MS m/z [M+H] ⁺ |
|----------|--|---|---------------------------|
| 30 | (4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(3-hydroxypyrrolidin-1-yl)methanone |  | 430.2 |
| 31 | (4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-aminopiperidinyl)methanone |  | 443.2 |
| 32 | (4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-aminopiperidinyl)methanone |  | 442.2 |
| 33 | 5-(4-(cyclopropylmethylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine |  | 435.0 |
| 34 | 5-(4-(cyclopropylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine |  | 421.2 |
| 35 | (R)-(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(3-hydroxypyrrolidin-1-yl)methanone |  | 429.0 |

| Compound | Chemical name | Structure | MS m/z [M+H] ⁺ |
|-----------|--|-----------|------------------------------|
| 36 | (S)-(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(3-hydroxypyrrolidin-1-yl)methanone | | 429.0 |


Compounds 13 to 19 and 20 to 32 were synthesized according to schemes 1 and 5, respectively. Compounds 33 and 34 were synthesized according to scheme 1. The 5 separate enantiomer compounds 35 and 36 were obtained after chiral HPLC separation [using a Chiral Pak IA (250 X 4.6)mm 5u; Mobile Phase of 0.1% DEA in Hexane: Ethanol (40:60) at a flow rate of 1.0mL/min] of the mixture, compound 21 which was synthesized according to scheme 3.

10 The starting material generically described in the reaction schemes which were used to synthesized compounds of the Examples are listed in Table 2 below:

Table 2

| Intermediate's formula | Chemical name | Structure |
|------------------------|---|-----------|
| (iv) | 6-methoxypyridin-3-ylboronic acid | |
| (iv) | 6-(trifluoromethyl)pyridin-3-ylboronic acid | |
| (vi) | 4-(methylsulfonyl)phenyl boronic acid | |
| (vi) | 4-(trifluoromethyl)phenyl boronic acid | |
| (vi) | 4-carbamoylphenylboronic acid | |

| Intermediate's formula | Chemical name | Structure |
|------------------------|--|-----------|
| (vi) | 4-(morpholine-4-carbonyl)phenylboronic acid | |
| (vii) | 5-(4-(methylsulfonyl)phenyl)pyrazin-2-amine | |
| (vii) | 4-(5-aminopyrazin-2-yl)benzamide | |
| (v) | 5-bromo-3-(6-methoxypyridin-3-yl)pyrazin-2-amine | |
| (viii) | 3-bromo-5-(4-(methylsulfonyl)phenyl)pyrazin-2-amine | |
| (viii) | (4-(5-amino-6-bromopyrazin-2-yl)phenyl)(3-hydroxy pyrrolidin-1-yl)methanone | |
| (xix) | tert-butyl 4-(4-(5-amino-6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)benzoyl piperazine-1-carboxylate | |

| Intermediate's formula | Chemical name | Structure |
|------------------------|---|---|
| (xix) | tert-butyl 4-(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)benzoyl)piperazine-1-carboxylate |  |

Example 3: Anti-malarial *in vitro* efficacy of compounds according to the invention

The ability of aminopyrazine derivatives according to the invention to kill *P. falciparum* parasites and/or to inhibit its proliferation is tested as follows:

Assay 1: The protocol used was as described in the supplemental material to *Fiddock et al., 2004, Nature Reviews Drug Discovery, (3), p509.*

Assay 2: Compounds are incubated in the presence of 2 or 3% ring stage parasite (*P. falciparum* 3D7 or Dd2) and 0.3% hematocrite in a total assay volume of 50 µL, for 72 hours in a humidified atmosphere at 37°C, 5% O₂ and 5% CO₂, in Poly-D-lysine coated Cell Carrier Imaging plates (Perkin Elmer). After incubation plates are stained with DAPI (4', 6-diamidino-2-phenylindole, Invitrogen) in the presence of Saponin and Triton X-100 (Sigma-Aldrich) and incubated for a further 5 hours at RT in the dark before imaging on the OPERA™ HTS confocal imaging system (Perkin Elmer). The digital images obtained are then analyzed using the PerkinElmer Acapella spot detection software where spots which fulfil the criteria established for a stained parasite are counted. The % inhibition of parasite replication is calculated using DMSO and 2 µM Artemisinin control data.

EC₅₀s (ng/ml) are reported in Table 3 below against different strains of *P. falciparum* K1, NF54 (assay 1).

Table 3

| Compound | <i>P. falciparum</i> (K1) | <i>P. falciparum</i> (NF54) |
|----------|------------------------------|--------------------------------|
| | EC ₅₀ ng/mL | EC ₅₀ ng/mL |
| 1 | 17 | 16.5 |
| 2 | 4.0 | 4.1 |
| 3 | 4.8 | 6.0 |
| 4 | 4.9 | 5.7 |

| Compound | <i>P. falciparum</i> (K1) | <i>P. falciparum</i> (NF54) |
|----------|------------------------------|--------------------------------|
| | EC ₅₀ ng/mL | EC ₅₀ ng/mL |
| 5 | 5.8 | 7.8 |
| 6 | 3.0 | 3.5 |
| 7 | 4.4 | 4.4 |
| 8 | 2.1 | 2.3 |
| 9 | 4.0 | 4.6 |
| 10 | 4.1 | 3.8 |
| 11 | 3.1 | 2.7 |
| 12 | 4.5 | 6.9 |
| 13 | 18 | 18 |
| 15 | 7.1 | 8.5 |
| 17 | 8.7 | 9.3 |
| 18 | 4.5 | 5 |
| 19 | 7 | 8.3 |
| 20 | 5.5 | 8.2 |
| 21 | 2.9 | 4.1 |
| 22 | 4.0 | 4.5 |
| 23 | 2.2 | 2.4 |
| 24 | 3.1 | 4.3 |
| 25 | 2.6 | 3.1 |
| 26 | 4.3 | 5.9 |
| 27 | 2.2 | 3.2 |
| 28 | 10 | 17 |
| 29 | 4.8 | 8.8 |
| 30 | 5.2 | 8.6 |
| 31 | 7.6 | 8.5 |
| 32 | 2.9 | 4.3 |
| 33 | 5.6 | 8.2 |
| 34 | 4.0 | 4.7 |
| 35 | | 3.2 |
| 36 | | 2.6 |

These data show that aminopyrazine derivatives according to the invention are able to inhibit parasite proliferation in infected human erythrocytes. Activities of compounds of the invention against different strains of *P. falciparum* as measured by EC₅₀ in the above assays are ≤ 20 ng/mL.

Example 4: Anti-malarial *in vivo* efficacy of compounds according to the invention

The ability of aminopyrazine derivatives according to the invention to show antimalarial efficacy *in vivo* can be tested by using the protocols described in the supplemental material to *Fidock et al., 2004, Nature Reviews Drug Discovery, (3), p 509*.


Table 4 below show the percentages of inhibition of parasitemia following 4 daily oral doses.

Table 4

| Compound | 3 mg/kg po | 10 mg/kg po |
|-----------------|-------------------|--------------------|
| 2 | 94.0 | 99.9 |
| 3 | 99.9 | 99.9 |
| 4 | 99.9 | 99.9 |
| 5 | 99.4 | 99.9 |
| 6 | 99.9 | 99.9 |
| 7 | 81.0 | 99.8 |
| 8 | 99.9 | 99.9 |
| 11 | 99.9 | 99.9 |
| 12 | 99.9 | |
| 13 | 99.9 | 99.9 |
| 17 | 99.6 | |
| 21 | 99.6 | |
| 23 | 98.7 | |
| 24 | 87.6 | |
| 25 | 90 | |
| 27 | 88 | |
| 35 | 99.9 | 99.9 |
| 36 | 99.9 | 99.9 |

Claims

1. An aminopyrazine according to Formula (I),



(I)

5 wherein X is CR¹ or N; Y is selected from CF₃, -C(O)-NR³R⁴; O-R⁶; SO₂-R⁶; R¹ is selected from H and halogen; R² is selected from SO₂-R⁵ and -C(O)-R¹⁰; R³ and R⁴ are independently selected from H and optionally substituted C₁-C₆ alkyl; R⁵ is selected from -NR⁷R⁸ and R⁹; R⁶ is optionally substituted C₁-C₆ alkyl; R⁷ and R⁸ are independently selected from H and optionally substituted C₁-C₆ alkyl; R⁹ is optionally substituted C₁-C₆ alkyl or optionally substituted C₃-C₈ alkyl; R¹⁰ is-NR¹¹R¹²; R¹¹ and R¹² are independently selected from H and optionally substituted C₁-C₆ alkyl or NR¹¹R¹² form together an optionally substituted heterocycloalkyl; as well as pharmaceutically acceptable salts, complexes, hydrates, solvates, or polymorphs, tautomers, geometrical isomers, optically active forms and pharmaceutically active derivative thereof..

10

2. An aminopyrazine according to claim 1 wherein X is N.
3. An aminopyrazine according to claim 1 wherein X is CR¹.
4. An aminopyrazine according to any one of claims 1 to 3 wherein Y is CF₃.
5. An aminopyrazine according to any one of claims 1 to 3 wherein Y is -C(O)-NHR³.
- 20
6. An aminopyrazine according to any one of claims 1 to 3 wherein Y is SO₂-R⁶.
7. An aminopyrazine according to any one of claims 1 to 6 wherein R² is SO₂-R⁵.
8. An aminopyrazine according to any one of claims 1 to 6 wherein R² is SO₂-R⁹.
9. An aminopyrazine according to any one of claims 1 to 6 wherein R² is SO₂-R⁹ and R⁹ is optionally substituted C₁-C₆ alkyl.

10. An aminopyrazine according to any one of claims 1 to 6 wherein R² is -C(O)-R¹⁰.
11. An aminopyrazine according to claim 10 wherein NR¹¹R¹² form together an optionally substituted heterocycloalkyl.
- 5 12. An aminopyrazine according to claim 10 wherein R¹¹ and R¹² are independently selected from H and optionally substituted C₁-C₆ alkyl.
13. An aminopyrazine according to any one of claims 1 to 12 wherein the aminopyrazine is selected from the following group:
3-(6-methoxypyridin-3-yl)-5-(4-(methylsulfonyl)phenyl)pyrazin-2-amine;
10 5-(4-(methylsulfonyl)phenyl)-3-(4-(trifluoromethyl)phenyl)pyrazin-2-amine
5-(4-(methylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine;
15 4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)benzamide;
4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)benzamide;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-methyl
20 piperazin-1-yl)methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-methyl
piperazin-1-yl)methanone;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(piperazin-1-yl)
25 methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(piperazin-1-yl) methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(morpholino)
30 methanone;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(morpholino)
methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-methyl-
1,4-diazepan-1-yl)methanone;
4-(5-amino-6-(3-fluoro-4-(trifluoromethyl)phenyl)pyrazin-2-yl)benzamide;
4-(5-amino-6-(4-(methylsulfonyl)phenyl)pyrazin-2-yl)benzamide;

4,4'-(3-aminopyrazine-2,6-diyl)dibenzamide;
4-(3-amino-6-(4-carbamoylphenyl)pyrazin-2-yl)-N-methylbenzamide;
4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)-N-methylbenzene
sulfonamide;
5-(4-(ethylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine;
5-(4-(isopropylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-
amine;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-(tert-butyl)
piperazin-1-yl)methanone;
10 (4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(3-hydroxy
pyrrolidin-1-yl)methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-hydroxy
piperidin-1-yl)methanone;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-hydroxy
15 piperidin-1-yl)methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-(tert-
butyl)piperazin-1-yl)methanone;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-methyl-1,4-
diazepan-1-yl)methanone;
20 (4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(1,4-
diazepan-1-yl)methanone;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(1,4-diazepan-1-
yl)methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(3-amino
25 pyrrolidin-1-yl)methanone;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(3-amino
pyrrolidin-1-yl)methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(3-hydroxy
pyrrolidin-1-yl)methanone;
30 (4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-amino
cyclohexyl)methanone;

(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-amino cyclohexyl) methanone;

5-(4-(cyclopropylmethylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl) pyrazin-2-amine; and

5-(4-(cyclopropylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine; as well as pharmaceutically acceptable salts, complexes, hydrates, solvates, or polymorphs, tautomers, geometrical isomers, optically active forms and pharmaceutically active derivative thereof.

14. An aminopyrazine according to any one of claims 1 to 13 for use as a medicament.

10 15. A pharmaceutical formulation containing at least one aminopyrazine according to any one of claim 1 to 13 and a pharmaceutically acceptable carrier, diluent or excipient thereof


15 16. A pharmaceutical formulation according to claim 15 further comprising an antimalarial agent.

17. An aminopyrazine according to any one of claims 1 to 13 for use in the prevention and/or treatment of malaria



20 18. A method for preventing or treating malaria in a patient, wherein the method comprises administering an effective amount of an aminopyrazine according to according to any one of claims 1 to 13 or a formulation thereof according to any one of claims 15 or 16 in a patient in need thereof.

19. An aminopyrazine according to any one of claims 1 to 13 or a method according to claim 18 wherein the aminopyrazine is to be administered in combination with a co-agent useful in the treatment of malaria.

25 20. A process for the preparation of an aminopyrazine derivative according to Formula (I) comprising the step of reacting a intermediate of Formula (v) with a boronic acid of Formula (vi) under Suzuki reaction conditions to lead to a compound of Formula (I):




wherein X, Y and R¹ are as defined in any one of the preceding claims and A is




21. An intermediate of Formula (v) wherein A is:

5 22. An intermediate according to claim 21 wherein the intermediate is 5-bromo-3-(6-methoxypyridin-3-yl)pyrazin-2-amine.

23. A process for the preparation of an aminopyrazine derivative according to
10 Formula (I) comprising the step of reacting a derivative according to Formula
(viii) with a boronic acid of Formula (iv) under Suzuki reaction conditions to
lead to a compound of Formula (I):




wherein A, D, X, Y and R¹ are as defined in any one of the preceding claims.



24. An intermediate of formula (viii) wherein D is

25. An intermediate according to claim 24 wherein the intermediate is 3-bromo-5-(4-(methylsulfonyl) phenyl)pyrazin-2-amine or (4-(5-amino-6-bromopyrazin-2-yl)phenyl)(3-hydroxypyrrolidin-1-yl)methanone

26. A process for the preparation of an aminopyrazine derivative according to Formula (I) comprising the step of reacting a derivative according to Formula (**xix**) in TFA to lead to a compound of Formula (V):



wherein A, X, Y and R¹ are as defined in any one of the preceding claims.

10 27. An intermediate of formula (xix) wherein the intermediate is selected from the following group: tert-butyl 4-(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)benzoyl) piperazine-1-carboxylate and tert-butyl 4-(4-(5-amino-6-(6-(trifluoromethyl) pyridin-3-yl)pyrazin-2-yl)benzoyl) piperazine-1-carboxylate.

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2013/051235

A. CLASSIFICATION OF SUBJECT MATTER

| | | | | | |
|------|------------|------------|------------|------------|------------|
| INV. | C07D401/04 | C07D401/10 | C07D401/14 | C07D413/10 | C07D241/26 |
| | A61K31/444 | A61K31/497 | A61P33/06 | | |

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|---|-----------------------|
| X | WO 2011/086531 A2 (MMV MEDICINES FOR MALARIA VENTURE; WITTY MICHAEL JOHN; HARDICK DAVID M) 21 July 2011 (2011-07-21) page 2; claims 1-29; examples 1,2,44 ----- | 1-27 |
| A | WO 2008/074997 A1 (CANCER REC TECH LTD [GB]; RAYNHAM TONY MICHAEL [GB]; HAMMONDS TIMOTHY) 26 June 2008 (2008-06-26) the whole document ----- | 1-15, 20-27 |
| A | WO 2007/147874 A1 (BIOVITRUM AB PUBL [SE]; JENMALM JENSEN ANNIKA [SE]; RINGOM RUNE [SE];) 27 December 2007 (2007-12-27) the whole document ----- -/- | 1-15, 20-27 |

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

| | |
|---|--|
| Date of the actual completion of the international search | Date of mailing of the international search report |
|---|--|

3 June 2013

13/06/2013

| | |
|--|--------------------|
| Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016 | Authorized officer |
|--|--------------------|

Goss, Ilaria

INTERNATIONAL SEARCH REPORT

| |
|------------------------------|
| International application No |
| PCT/IB2013/051235 |

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| A,P | US 2012/225857 A1 (AUGERI DAVID JOHN [US] ET AL) 6 September 2012 (2012-09-06) Close related compound with RN: 1396771-92-8; claims 1-22 ----- | 1-15, 20-27 |
| A | DAVID A. FIDOCK ET AL: "Antimalarial drug discovery: efficacy models for compound screening", NATURE REVIEWS DRUG DISCOVERY, vol. 3, no. 6, 1 June 2004 (2004-06-01), pages 509-520, XP055061407, ISSN: 1474-1776, DOI: 10.1038/nrd1416 the whole document ----- | 1-27 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

| |
|---|
| International application No PCT/IB2013/051235 |
|---|

| Patent document cited in search report | Publication date | Patent family member(s) | | | Publication date |
|--|------------------|-------------------------|---|--|--|
| WO 2011086531 | A2 | 21-07-2011 | CA 2787121 A1 CN 102812006 A EP 2526090 A2 US 2012295905 A1 WO 2011086531 A2 | | 21-07-2011 05-12-2012 28-11-2012 22-11-2012 21-07-2011 |
| WO 2008074997 | A1 | 26-06-2008 | AU 2007336046 A1 CA 2673582 A1 EP 2114887 A1 JP 2010513433 A US 2011098325 A1 WO 2008074997 A1 | | 26-06-2008 26-06-2008 11-11-2009 30-04-2010 28-04-2011 26-06-2008 |
| WO 2007147874 | A1 | 27-12-2007 | AT 456565 T AU 2007263017 A1 BR P10713328 A2 CA 2654358 A1 CN 101472912 A EP 2044051 A1 ES 2340093 T3 JP 2009541268 A RU 2009101911 A US 2008039450 A1 WO 2007147874 A1 | | 15-02-2010 27-12-2007 30-10-2012 27-12-2007 01-07-2009 08-04-2009 28-05-2010 26-11-2009 27-07-2010 14-02-2008 27-12-2007 |
| US 2012225857 | A1 | 06-09-2012 | TW 201247626 A US 2012225857 A1 WO 2012121992 A1 | | 01-12-2012 06-09-2012 13-09-2012 |